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ABSTRACT 
 
Corrine Mellin; Improving antiemetic guideline adherence for adult patient’s  
receiving highly emetogenic chemotherapy (HEC) 
(Under the direction of Deborah Mayer) 
 
A quality improvement project was implemented to improve adherence to evidence based 
antiemetic guidelines for patient receiving HEC, and ultimately improve the rates of chemotherapy 
induced nausea and vomiting. Chemotherapy induced nausea and vomiting (CINV) can be prevented in 
70-80% of cases when guidelines are followed; however, despite being recently updated, there is evidence 
that guideline utilization is less than optimal. Two potential reasons for inadequate CINV guideline 
adherence is provider lack of knowledge and/or how to implement them into practice.  
Methods: 
     A retrospective chart analysis prior to the intervention was performed on 86 patients to assess for 
the presence of CINV and use of antiemetics. Pre-intervention, an electronic anonymous survey was 
provided to nurses and APP’s. In-person education interventions were provided to nurses and APP’s over 
one month. An immediate post and three month post-intervention survey was provided to RN’s and 
APP’s. Three months post-implementation, a retrospective chart analysis was performed on 37 patients to 
again assess for presence of CINV and use of antiemetics.  
Results: 
     In a pre-intervention chart review of the 86 patients, 42 (48.8%) experienced CINV with only 6 
(7%) receiving guidelines appropriate antiemetic prophylaxis. Out of 82 nurses, 60 participated in the pre-
intervention survey scoring an average percent correct of 57.7%, and five of six APP’s participating 
scoring an average of 60.8%. Immediately post-intervention 55 of 78 nurse participated scoring an 
average percent correct of 66.1%, and all six APP’s participated scoring 71.9%. Three months post-
		 iv		
intervention 41 of 74 nurses participated scoring an average of 66.2%, and five of the six APP’s 
participated scoring a 70.8%. Of the 37 patients selected for three months post-intervention chart review, 
14 (37.8%) experienced CINV with 8 (21.6%) receiving guideline appropriate antiemetic prophylaxis.  
Conclusion:  
 The study demonstrates an effective approach in improve provider adherence to antiemetic 
guidelines, which resulted in a decrease in the rates of CINV. Findings also demonstrate the need for 
guideline reinforcement and continuing education on recent updates and chart audits to ensure continued 
adherence, allowing for the best evidence base care to be provided to patients.  
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CHAPTER 1: INTRODUCTION 
Problem Introduction 
 
Chemotherapy induced nausea and vomiting (CINV) has been ranked as one of the most dreaded 
side effects associated with chemotherapy, and is a persistent problem for about 40-80% of patients 
receiving treatment (Viale, Grande, Moore, 2012; Vidall, Sharma, Amlani, 2016). The likelihood and 
severity of CINV varies depending on the chemotherapy agents used (Danial & Waddell, 2016). 
Chemotherapy agents are grouped into four categories depending on their ability to cause CINV without 
appropriate prophylaxis (i.e. emetogenic potential); highly emetogenic (>90% will experience CINV), 
moderately emetogenic (30-90% will experience CINV), and low emetogenic (10-30% experience CINV) 
and minimal (<10% experience CINV) (Fernandez-Ortega et al., 2012). CINV is classified into four 
different types; acute, delayed, breakthrough, and anticipatory. Acute CINV occurs within the first 24 
hours after initiation of treatment, whereas delayed CINV occurs 24 hours after treatment and may persist 
up to five days (Boccia, 2013). Breakthrough CINV occurs in patients despite being given the appropriate 
prophylactic treatment (Navari & Aapro, 2016). Anticipatory CINV is nausea or emesis that occurs as a 
conditioned response from prior experience with chemotherapy and CINV (Navari & Aapro, 2016). 
CINV can lead to complications such as metabolic imbalances, anorexia, dehydration, weakness, and 
weight loss (Navari, 2016). It can also be associated with more serious complications such as esophageal 
tears, fractures, decline in mental/behavioral health, and poor wound healing (Navari, 2016).  
Current treatment guidelines commonly used for prevention and management of CINV include 
combined recommendations from the American Society of Clinical Oncology (ASCO), National 
Comprehensive Cancer Network (NCCN), and Multinational Association of Supportive Care in Cancer 
(MASCC) (Boccia, 2013). Clinical practice guidelines for CINV incorporate the most recent available 
research, along with use of an expert team to establish optimal treatment approaches (Boccia, 2013).  
		 2		
UNC Hospital has chosen to use a combination of the ASCO and NCCN guidelines to guide the 
creation of treatment plans and standing order sets to manage CINV based on the emetic potential of the 
chemotherapy regimen. With the recent switch to EPIC electronic records, the EPIC governance group 
used the ASCO guidelines to update standing order sets for chemotherapy templates. There are slight 
differences among these guidelines, with the unanimous consensus focused on appropriate prevention and 
management of CINV being critical in patient care (Schwartzberg, 2012). All three of the guidelines 
(ASCO, NCCN, and MASCC) have all been updated within the last year. These guidelines were created 
to serve as a tool for practitioners to appropriately implement and treat patients using the latest 
recommendations based on clinical research in practice (Danial & Waddell, 2016).  
Problem Description/Background 	
The prevalence of CINV continues despite many recent advances in antiemetic therapy since the 
1990’s, and continuous guideline updates for clinical practice (Viale et al., 2012). CINV can be prevented 
in about 70-80% of cases with appropriate antiemetic prophylaxis and management (Fernandez-Ortega et 
al., 2012). Yet despite recently updated guidelines, there is evidence that utilization of guidelines is less 
than optimal (Fernandez-Ortega et al., 2012). In oncology, especially with supportive care, the lack of 
“life or death” outcomes related to incorrect decisions or adherence, allows providers more autonomy for 
practice (Grunberg, 2009). Thus, implementing guidelines for CINV has proven difficult (Grunberg, 
2009). Another consideration for the lack of guideline adherence is that health care providers may not be 
familiar with specific guidelines (Grunberg, 2009). Burmeister et al. (2012) supported the importance of 
health care providers undergoing periodic education on supportive care measures, along with continued 
education on guideline adherence. One study demonstrated that health care providers need to increase 
their awareness on the actual incidence of CINV (Viale et al., 2012). Another study suggested that 
healthcare providers lack knowledge on how to effectively implement guidelines into practice (Van Laar, 
Desai, & Jatoi, 2015). Very few studies have evaluated approaches to improve provider adherence with 
guidelines, and those that have showed limited success (Jordan et.al., 2015). Another complicating issue 
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with guideline adherence is the complicated management of multi-day chemotherapy regimens, with 
antiemetic decisions further complicated by the overlap of acute and delayed emesis (Boccia, 2013). This 
issue is under represented in literature, however the guidelines do suggest ways to effectively prevent and 
manage CINV with multi-day chemotherapy (Boccia, 2013).  
Clinical practice guidelines recommend several different three drug antiemetic combination 
regimen for the prevention of CINV after administration of HEC (NCCN, 2017). Thc commonly 
suggested regimen is a combination of 5HT3 antagonist, dexamethasone, and NK-1 antagonist (NCCN, 
2017). The NCCN and MASCC guidelines include olanzapine, along with 5HT3 antagonist and 
dexamethasone, as an alternative three drug regimen to the NK-1 antagonist (NCCN, 2017). There have 
been numerous studies looking at the efficacy of olanzapine, all of which show highly effective rates of 
CR (complete response), especially when in combination for the prevention of acute and delayed CINV 
with HEC (NCCN, 2017). Olanzapine has been shown to be highly effective in the delayed phase of 
CINV, and is also cost-effective when compared to the NK1 RA’s (Wang et. al., 2014). Though many 
providers worry about the side effects of olanzapine, given its use as an atypical antipsychotic, the most 
frequently experienced are sedation and weight gain which may not be concerning for oncology patients 
(Wang et. al., 2014).  
In a study by Vidall et. al., nearly one in five patients reported that during their first cycle of 
chemotherapy they felt their antiemetic coverage was insufficient. In addition, 42% said that at least two 
medications had to be changed in order to achieve symptoms control (Vidall et. al., 2016). Both symptom 
control and the patients quality of life should be considered one of the main goals of care, with studies 
showing there needs to be more efforts in encouraging healthcare workers to adhere to guidelines and 
treat prophylactically.  
With the cost of cancer therapy rapidly increasing, the cost in managing CINV appropriately with 
newer drugs also is continuing to rise (Viale et. al., 2012). Although the costs of antiemetics are 
significantly lower than the cost of chemotherapy agents, the combination of both increases the financial 
burden of treatment costs (Viale et. al., 2012). However, the cost of antiemetics must be heavily weighed 
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against the price of inadequate treatment of CINV (Viale et. al., 2012). The monetary value of the 
antiemetic does not represent the total physical and psychological effects, including the suffering of those 
patients experiencing the most dreaded side effect of chemotherapy (Viale et. al., 2012). There can also be 
significant costs associated with the need for prolonged hospitalization, frequent clinic/emergency 
department visits, additional medications, and even a separate admission for management of CINV effects 
(Burke, Wisniewski, & Ernst, 2011).  
The prevention of CINV is critical to maximizing patient’s quality of life during their cancer 
treatment (Thompson, 2012). Uncontrolled CINV can place a substantial burden on the patient and their 
caregivers, impacting their quality of life and physical wellbeing (Boccia, 2013). Patients who experience 
CINV are often discouraged from finishing chemotherapy treatment, as it effects both quality of life and 
the patients ability to carry out activities of daily living (Aapor et. al., 2012). Many studies have noted 
that the intensity and duration of CINV are two factors heavily associated with a larger impact on quality 
of life (Viale et. al., 2012). This is very important to consider, as newer chemotherapy regimen maximize 
doses to create shorter regimen durations, thus the intensity and duration should be heavily considered in 
relation to expected CINV (Viale et. al., 2012). Not only does CINV decrease the compliance with 
chemotherapy treatments, but can also cause numerous other complications such as anorexia, metabolic 
imbalances, and poor nutritional support (Daniel & Waddell, 2016). These symptoms in combination with 
the associated morbidity of CINV, has resulted in some patients withdrawing from a potentially useful 
and/or curative treatment (Daniel & Waddell, 2016). Fortunately, the appropriate use of modern and new 
antiemetic agents has successfully shown a significant reduction or elimination of CINV in about 70-80% 
of patients (Daniel & Waddell, 2016). Research has definitively shown that following the clinical 
guidelines will significantly improve CINV control when compared to inconsistent guideline use (Boccia, 
2013; Viale et. al., 2015).   
 
 
		 5		
Purpose of the Project 	
The purpose of this DNP project is to determine the rate of and barriers to adherence to 
antiemetic guidelines for chemotherapy induced nausea and vomiting in hospitalized cancer adults 
receiving highly emetogenic chemotherapy. 
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CHAPTER 2: REVIEW OF LITERATURE 	
A review of literature was conducted using CINHAL and PubMed. Search terms include: 
“chemotherapy induced nausea and vomiting”, “CINV management”, “antiemetic guideline adherence”, 
“CINV breakthrough management”, and “CINV adherence”. Search limits include those articles include 
those articles published in 2010 or later. Articles in 2010 or later were targeted to ensure incorporation of 
the most recent guideline updates and the newer antiemetics suggested for management of HEC. Articles 
chosen consisted of journal articles, editorials, evidence based practice guidelines, literature reviews, 
surveys, and research articles. Other searches were performed on Education Full Text (via EBSCOHost), 
International Pharmaceutical Abstracts (via EBSCOHost) using: “evidence based practice 
implementation”; “provider adherence”; “cost analysis”; and “chemotherapy vomiting management”. 
Articles were excluded if they used non-pharmacological management, were about specific drug trials, 
supportive care for individual cancer types, or discussed patient adherence to antiemetics only.   
Effects of Chemotherapy Induced Nausea and Vomiting  	
CINV is one of the most commonly experienced and feared symptoms in chemotherapy treatment 
(Viale et al., 2012; Hilarius et al., 2012; Fernandez-Ortega et al., 2012; Ng, Hutton, & Clemons, 2015; 
Schwartzberg, Grunberg, & Kris, 2011; Underhill, Chicko, & Berry, 2015; Grassi et al., 2015; Boccia, 
2013). Adequate control of CINV remains a vitally important challenge in caring for cancer patients as it 
affects the patient, caregivers, healthcare providers, and the healthcare system (Schwartzberg, Grunberg, 
& Kris, 2011). The prevention of CINV is possible when the evidence-based practice recommendations 
are adequately utilized (Viale et al., 2012). 
CINV has a significant impact on the patient’s quality of life and treatment outcomes (QoL) 
(Fernandez-Ortega et al., 2012; Haiderali et. al., 2011; Grassi et al., 2015; Boccia, 2013, Middleton, 2011; 
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Hilarius et al., 2012; Davidson et al., 2011; Moradian & Howell, 2015). Despite improvements in 
antiemetic treatment and the emergence of new drugs, CINV continues to be a significant problem, with 
45-65% experiencing nausea, and 15-25% experiencing vomiting (Grassi et al., 2015; Ng, Hutton, & 
Clemons, 2015; Hawkins & Grunberg, 2009; Boccia, 2013; Underhill, Chicko, & Berry, 2015). CINV is a 
common side effect experienced by cancer patients, resulting in debilitating side effects that interfere with 
their ability to perform daily activities (Haiderali et al., 2011). Uncontrolled CINV may require patients to 
present for rehydration and emesis control, which may require an emergency department visit or 
hospitalization (Navari, 2015). Patients who develop electrolyte imbalances from CINV are at a greater 
risk of developing serious complications (Navari, 2015). Severe or uncontrolled CINV can result in 
patients self-electing to discontinue chemotherapy treatment (Viale et al., 2012). Healthcare providers are 
also effected by uncontrolled CINV, which results in a disruption to scheduled treatment plans, often 
requiring providers to make a difficult decision to delay or discontinue potentially curative treatments 
(Celio,  Ricchini, & De Braud, 2013).  
Lack of Guideline Adherence  	
There is a lack of adherence to antiemetic guidelines for prevention and management of CINV by 
both advanced practice providers and nurses (Hilarius et al., 2012; Schwartzberg, Grunberg, & Kris, 
2011; Jordan et al., 2014; Viale et al., 2012; Jordan, Jahn, & Aapro, 2015; Fernandez-Ortega et al., 2012; 
Caracuel et al., 2015; Escobar et al., 2015; Schwartzberg, 2014; Boccia, 2013). The reason for low 
compliance with guidelines is multifactorial and found in all areas of healthcare, not just with antiemetic 
guidelines (Jordan et al., 2014). Fortunately, guidelines are very useful tools for providers to appropriately 
employ  and integrate the newest clinical research into practice (Daniel & Waddell, 2016; Jordan et. al., 
2014). Despite the recently updated and easily accessible NCCN and ASCO guidelines, there is evidence 
that adherence and use of these guidelines is less than optimal (Fernandez-Ortega et al., 2012). 
Recent studies show that providers overestimate the control of CINV in patients receiving highly 
emetogenic chemotherapy (HEC), demonstrating the need to increase awareness of the incidence of 
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CINV (Viale et al., 2012; Jordan, Jahn, & Aapro, 2015; Hilarius et al., 2012; Schwartzberg, Grunberg, & 
Kris, 2011). More than 75% of  providers and nurses underestimate the rates and incidence of delayed 
emesis after administration of highly emetogenic chemotherapy (Rha et. al., 2016; Schwartzberg, 
Grunberg, & Kris, 2011; Hilarius et al., 2012; Schwartzberg, 2014; Viale et al., 2012; Boccia, 2013; 
Caracuel et. al., 2015). Also, health care providers lack knowledge on how to implement guidelines 
effectively into practice (Van Laar et. al., 2015). Less than optimal adherence to guidelines results in 
deficient control of CINV, which can lead to excessive use of health care resources and interfere with 
patients’ compliance with treatment regimen (Fernandez-Ortega et al., 2012). Failure of the healthcare 
teams to understand CINV and implement guidelines contributes to poorer patient outcomes and plays a 
major role in the problem (Hawkins & Grunberg, 2009). It is critical that providers recognize the 
prevalence of CINV to minimize nausea and vomiting to allow patients to maintain quality of life and 
focus on their cancer treatments (Jordan et al., 2014). 
Cost Associated with CINV 	
CINV can be associated with substantial healthcare resource utilization, as patients may require 
additional medical care to treat the consequences and symptoms CINV (Burke, Wisniewski, & Ernst, 
2011; Viale et al., 2012;     Fernandez-Ortega et al., 2012; Haiderali et. al., 2011; Craver, Gayle, Balu, & 
Buchner, 2011). Deficient control of CINV requires rescue medication use, emergency department visits, 
and/or hospitalizations, resulting in increased use of health care resources and cost of medical care 
(Hawkins & Grunberg, 2009; Fernandez-Ortega et al., 2012; Haiderali et. al., 2011). The direct cost of 
antiemetics should be balanced against the cost of inadequately prevented and managed CINV, which 
often includes unnecessary or prolonged hospitalizations (Viale et al., 2012). There is also an indirect cost 
involving the missed time at work for both the patient and their caregivers (Viale et al., 2012; Haiderali 
et. al., 2011). 
One study by Burke et. al. showed that inpatient hospitalizations were the most common type of 
visit for CINV, with inpatient admissions after the first cycle amounting the highest cost, on average 
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$5,300 per visit. Also hospital visits after the first cycle of chemotherapy were most pronounced in those 
receiving HEC (Burke et. al., 2010). Through numerous studies assessing the cost burden of uncontrolled 
CINV, it can be said that the clinical and economic burden is substantial (Craver et. al., 2011, Burke et. 
al., 2010, Hideraldi et. al., 2011). Antiemetic costs can be potentially higher up front, however 
inadequately treated CINV can result in increased resource costs for both payers and institutions (Viale et. 
al., 2012; ). The most significant cost of inadequate antiemetic prophylaxis is patient suffering, therefore 
clinical guidelines should be utilized by healthcare providers in determining appropriate antiemetic 
prophylaxis (Viale et. al., 2012; Fernandez-Ortega et al., 2012; Craver et. al., 2011). In a study by 
Schwartzberg et. al., patients that received neurokinin-1 receptor antagonists (NK1-RA) had lower rates of 
resource utilization, which may suggest that NK1-RA’s used in accordance to national guidelines can 
reduce healthcare resource utilization.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
		 10		
 
 
 
 
 
CHAPTER 3: CONCEPTUAL FRAMEWORK 
Conceptual Framework 	
Kurt Lewin’s Change Theory was developed in the area of psychology, and considered the start 
in the development of contemporary theories for change management and organizational change (Burnes, 
2004).  This theory consisted of four elements: (1) field theory, focuses on human behaviors; (2) group 
dynamics, which understands behavior of groups; (3) action research, analyzing situation and choosing 
best change process; and (4) three-step change model, consisting of unfreezing, moving, and refreezing 
steps (Medley & Akan, 2008). Field Theory was Lewin’s approach to mapping out an understanding for 
group behavior (Burnes, 2004). Action Research stressed that in order for change to be successful, change 
must occur at a group level, involving collaboration and participation of all those involved or concerned 
(Burnes, 2004). The idea of group dynamics is to veer away from individual behaviors, and rather focus 
on the behavior of the group as the emphasis for change (Burnes, 2004). Lewin’s theory of change, 
specifically utilization of the 3-step model, provides an organized step-wise approach to implementing the 
proposed education and overall change in practice.  
Unfreezing involves the ability to recognize the need for change in either an individual or a group 
setting, along with creating motivation for the change (Manchester et al., 2014). The first task in the 
unfreezing step requires the identification of a problem or assessing the need for a change in practice 
(Buonocore, 2004). This need for change could be determined based off quality improvement initiative 
data, practitioner or nurse queries as to why we do things the way that we do, or newer evidence based 
research (Buonocore, 2004). The extreme importance of this step is to clarify and prove that a problem 
really does exist (Buonocore, 2004). Moving is the stage of change implementation where data is 
obtained, the problem is diagnosed, the action for implementation of change is planned, change is 
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implemented, and follow up assessment is performed to stabilize or ‘refreeze’ the change (Tools, 2007). 
These implemented changes are embraced by utilizing effective communication, along with empowering 
members to embrace new changes and behaviors (Tools, 2007). Solutions for problems are typically 
education on and implementation of protocols, procedures, or practice guidelines (Buonocore, 2004). 
Refreezing is when the new practice has shaped the organization, and reinforcements for the new 
procedures are utilized to increase the probability of sustaining them (Manchester et al., 2014). 
Successfully implementing this last stage is why Lewin saw it most effective to focus the change process 
at a group level. Unless “norms” of the group are effectively transformed, any change to individual 
behavior will not remain (Burnes, 2004).  
Lewin’s 3-step change model will be used as a framework for the project intervention, while 
incorporating important aspects from the other three elements. Lewin’s change theory is relevant to 
understanding how to invoke influential changes in a practice in regards to provider education on 
evidence based practices (Tools, 2007). 
 
 
 
  
		 12		
 
 	
 
 
CHAPTER 4: PROJECT AIMS/OUTCOME 	
A combination intervention was proposed including (1) data collection of patients receiving HEC 
to determine rates of nausea and vomiting and (2) an education session for health care providers on 
current guidelines. The goal of the education sessions was to increase adherence to antiemetic guidelines, 
which ultimately would improve rates of emesis experienced by patients receiving HEC.  
Primary Aim/Subjects 	
The primary aim was to determine the rates of both nausea and vomiting experienced by patients 
receiving HEC. Vomiting/emesis is defined as the actual forceful upward expulsion of contents from the 
stomach (Wood, Chapman, & Eilers, 2011). Nausea is an unpleasant sensation experienced in the back of 
the throat and epigastric area that may or may not result in the expulsion of contents from the stomach 
(Wood, Chapman, & Eilers, 2011). While nausea is a “patient reported outcome”, for the purposes of this 
project, records of nausea were assessed through patient charts in the assessment tab and nursing notes. 
Patient subjects were selected using an i2b2 data query, a web application where you can input your 
inclusion/exclusion criteria that provides de-identified UNC Health Care data to help determine the 
feasibility of research/trials. The i2b2 data query resulted in 400 patients that met inclusion criteria from 
July 2015 to July 2016. The inclusion criteria included both male and females, 18 years or older, 
receiving a highly emetogenic chemotherapy (HEC) agent for cancer  on the inpatient unit at UNC cancer 
hospital (Appendix ).  
Secondary Aim/Subjects 	
  A secondary aim focused on improving healthcare provider adherence to the clinical practice 
guidelines for antiemetics in patients receiving HEC by using a powerpoint education session aimed at 
educating providers on the guidelines. The education intervention participants for the project targeted six 
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advanced practice providers (APP’s), which are both PA’s and NP’s, along with 83 staff nurses that work 
on the inpatient hematology/oncology unit. The intervention focused on the APP’s from a provider 
perspective in regards to guidelines implementation in practice. Physicians (including residents and 
interns) were not included, since they rotate off the unit every six weeks, and there would be no time to 
assess the effectiveness of their education over an extended period of time. The APP’s are part of the 
medical team, directly overseeing care for the majority of patients admitted for chemotherapy, as well as 
responsible for reviewing the orders and adjusting medications in the chemotherapy orders. Unlike the 
medical residents and interns that rotate around the hospital every six weeks, the APP’s are fixed on the 
unit. APP’s received the educational training on the use of antiemetic guidelines (both ASCO and 
NCCN), with the goal of improving implementation of these guidelines on the unit. The staff nurses on 
the unit were targeted because of their role in administration of appropriate antiemetics to the patients.  
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CHAPTER 5: METHODOLOGY 
Study Design 	
The method for this project is a Quality Improvement Project will be the PDSA (Plan, Do, Study, 
Act) method. The PDSA cycle is a series of steps to assist in gaining knowledge to allow for continual 
process improvement (AAN, 2013). The cycle begins with the Plan step, which help identify the project’s 
purpose, formulate a theory, and put a plan into action (AAN, 2013). The second step is the Do step, 
when the plan is implemented, followed by the Study step when outcomes are monitored and the plan is 
assessed for progress or problem areas (AAN, 2013). Lastly, the Act step ends the cycle integrating what 
was learned to adjust future goals and methods (AAN, 2013). The PDSA model is a never-ending cycle of 
continuous improvement (AAN, 2013). The goal of this project is to implement the use of antiemetic 
guidelines, which are the recognized standards of practice, to directly benefit the care of patients 
receiving highly emetogenic chemotherapy. The endpoint is to improve rates of chemotherapy-induced 
nausea and vomiting, and hopefully provide a successful method of education for providers to improve 
guideline adherence. 
Setting 	
    This study took place at UNC Cancer Hospital, on the inpatient adult hematology/oncology unit. UNC 
Cancer Hospital serves a variety of cancer patients. In total, the cancer hospital treats more than 135,000 
patients each year throughout North Carolina and surrounding states. The cancer hospital has one 
inpatient hematology/oncology unit, which as of April 2016 expanded from 34 to 53 beds to better serve a 
growing population of oncology patients. The unit is comprised of three medical hematology/oncology 
teams, otherwise known as Med E teams. One team (Med E1)  is responsible for the “liquid” tumors 
(leukemia, lymphoma, etc.), another team (Med E2) is responsible for the “solid” tumors. The last team 
(Med E3) is comprised of six APP’s responsible for scheduled chemotherapy admissions and newly 
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diagnosed patients with “liquid” tumors. There are a total of 83 staff nurses that work on the unit, 
including full-time, part-time, and per diem staff. This number did change a few times during the project 
as some staff left and others were newly hired.  
Tools 	
    For the selection of primary study subjects, an i2b2 data query tool was utilized to help determine 
appropriate subjects based on inclusion/exclusion criteria. Selected inclusion criteria helped to create a 
query tool targeting those patients that received HEC over one year’s time on the inpatient unit. This 
query tool was then submitted to the Carolina Data Warehouse (CDW), a central data source that houses 
clinical data from the UNC Health Care System from Epic (an electronic healthcare record). Patients 
selected utilizing this tool then became part of a retrospective chart analysis that helped determine 
previous rates of nausea and vomiting. Qualtrics, an online survey tool provided by UNC Chapel Hill for 
UNC-related problems, was used to create a survey to assess knowledge levels of both APP’s and staff 
nurses on antiemetic guidelines. The survey included 10 demographic/education questions for nurses, 6 
demographic/education sessions, and 14 questions assessing basic knowledge [describe how 
developed/reviewed/tested before deployment] such as how to find the guidelines, how to implement 
them into practice, how to utilize them, etc. There were also a few advanced knowledge questions with 
case studies testing application of the guidelines for nurses and APP’s separately.  
Ethical Considerations 	
All participants were given a consent information sheet the discussed what their participation in 
the project would entail, also discussing that their participation would be voluntary and completely 
anonymous. There was no written consent, which could potentially link the participant to the study, and 
instead all consents were verbal. All Qualtrics surveys completed by participants were anonymously 
submitted, to eliminate any embarrassment that could be felt for insufficient knowledge of the material or 
concerns about answering the demographic questions. These survey results were only reviewed by the 
principal investigator and co-investigator, before being combined into charts. There is no identifiable 
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information included in the study for any of the participants. This project underwent IRB review and was 
determined that the research presents no more than minimal risk of harm to the participants, and involved 
no consent that is normal required outside of the research context. [did this undergo IRB review? If so 
state that] 
Patients whose charts that were selected for the retrospective chart analysis were exempt from the 
need for participation consent. Informing the patient that an education study is being done to ensure that 
UNC and providers are adhering to guidelines, the subjects may unintentionally experience doubt and 
mistrust in the providers and treatment team. This could ultimately lead risk their treatment and overall 
health. Without utilizing the patients charts, there would be no way to definitively determine the lack of 
guidelines adherence to educate providers and RN's. There would also be no way to determine the rates of 
nausea and vomiting experienced by these patients. The importance of improving guidelines adherence 
among providers and RN's will significantly improve patient outcomes with CINV, and ultimately 
improve their health and experience with chemotherapy treatments as an inpatient at UNC. Therefore, a 
waiver of written consent was granted by the IRB for only patient’s whose charts would be part of the 
analysis. 
Primary Subject Selection 	
    Using the i2b2 data query, two lists were created using the inclusion criteria. Two lists were needed to 
specify the HEC agents; one for the individual HEC agents and one for the combination of anthracycline 
plus cyclophosphamide. These lists were then submitted to the CDW, which used the i2b2 queries to pull 
the patient’s medical record numbers (MRN’s). Once the lists of MRN’s were received, they were 
compared to exclude any duplicate patient’s/MRN’s, resulting in 308 patient charts total for retrospective 
analysis. Given the number of inclusion criteria and how the search database works, the CDW 
recommended that we verify all of the important parts of the inclusion criteria were present. The 
retrospective chart analysis started with reviewing the chemotherapy regimen given to ensure that it; 
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included a HEC agent, the regimen was given on the inpatient oncology unit and not on another 
unit/outpatient, and that it was given in the selected time frame.  
Secondary Subject Selection 	
    All nurses and APP’s on the inpatient hematology oncology unit were targeted as potential subjects. 
Each nurse was provided with a participant consent to explain what would be asked of them if they agreed 
to participate in this study. The consents were read over with the nurse and the APP, and their verbal 
consent was given if they agreed to participate. All nurses were asked, regardless of whether they were 
certified to given chemotherapy or not, and even newly hired nurses were included in the consent process 
for this project.  
Data Collection 	
Patient Charts. Data was collected from EPIC to determine the rates of nausea and vomiting in 
patients receiving HEC from July 2015 to July 2016 (pre-intervention) and from October 2016 to January 
2017 (post-intervention). The patient charts selected using the i2b2 query were used for the retrospective 
chart analysis to determine if nausea and/or vomiting did occur. Qualtrics was used to create a template 
for data collection to ensure all the same data points were collected on every patient. First things collected 
were basic patient demographics such as age, gender, race, and cancer diagnosis. The names of the 
chemotherapy regimen given, along with the individual chemotherapy agents name, route and dose, were 
collected next. The chemotherapy cycle number was also documented, as literature suggests that CINV 
rates are higher with the first cycle. Not all patients received cycle one in the inclusion time frame, 
therefore the earliest cycle given within the allotted time was the one utilized in the chart review. The 
presence of vomiting/emesis was found in the patient charts in the intake/output section as an occurrence 
or volume amount, in the assessment section under the gastrointestinal (GI) section, and/or in the nursing 
notes. The experience of nausea was found in the patient assessment section under the GI section, and/or 
in the nursing notes. Since the presence of nausea is a patient reported outcome, the nursing notes were 
utilized heavily for this section, which is were nausea is most often reported in patient charts. Nursing 
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notes/care plan notes are the notes written at the end of every shift by the nursing staff caring for the 
patient to summarize what happened during the day. This is most frequently where vomiting was 
quantified (ex: patient experience 2 episodes of emesis during the shift) and also were the presence of 
nausea in patients was noted. The number of times vomiting/emesis and/or nausea were experienced was 
collected, along with where the experience was charted. Lastly, the prophylactic antiemetics given as 
premedications were documented, which helped to determine if the prophylaxis antiemetics given 
followed the guidelines. Patient MAR’s (medication administration record) were assessed for the use of 
additional breakthrough antiemetic administration during their chemotherapy treatment. These were 
documented as name of drug, dose, route, and the number of times given over a span of dates. The 
patient’s MAR was assessed from the initial start of the chemotherapy regimen and up to five days after 
chemotherapy completion, which is the length of time in which breakthrough CINV can occur.  
Surveys.  	
Data collection with the surveys occurred three times during the project implementation; pre-
intervention, post-intervention, and three months post-intervention. There were two surveys, one for the 
nurses and one for the APP’s; each Qualtrics survey contained 21 questions for APP’s and 24 questions 
for nurses.. Surveys were administered by email through Qualtrics, which provided an anonymous link 
that could only be used the participant and would become inactive after they submitted the survey. This 
was how all three surveys were distributed to the nursing staff and APP’s. The first nine questions in the 
nurses survey and the first six questions in the APP survey were basic demographic questions, and the 
rest were to assess their knowledge of evidence based guidelines for prevention and management of 
CINV. Questions were developed using the evidence based guidelines and the targeted areas where 
providers lacked knowledge of guidelines determined by recent literature. Each survey was timed for 15 
minutes to ensure immediate responses and dissuade anytime for use of outside resources. Upon 
completion, the survey was electronically submitted to Qualtrics, which aided in the overall scoring of the 
surveys.  
		 19		
Nursing Survey.  	
Nursing surveys were developed to assess knowledge of the guidelines and how they are 
useful in preventing/managing CINV in outpatients. The pre-intervention surveys were provided 
to nursing staff three weeks before the education interventions began. Once all the education 
sessions for nursing staff were complete, the post intervention survey was sent out to nursing 
staff. This survey included the same questions as the pre-intervention survey, with questions and 
answers scrambled in their order. This was then compared to the pre-intervention survey scores to 
assess immediate knowledge improvement after education. Three months later, they were asked 
to take the same anonymous Qualtrics survey with same questions, just scrambled in order. This 
survey was compared to both the pre-intervention and initial post-intervention survey to assess 
knowledge retention among nursing staff (Appendix 1). 
APP Survey  	
APP surveys were developed to assess the knowledge in the utilization of the guidelines 
to prevent and/or manage CINV in patients. The pre-intervention survey was provided to the 
APP’s three weeks prior to when the education interventions began. When the one education 
session was complete, and the voice recorded powerpoint was sent out for the one APP who was 
unable to attend, the post-intervention survey was sent out to the APP’s. The post-intervention 
survey included the same questions as the pre-intervention survey, with the questions and answers 
scrambled in their order. This was used to compared to the pre-intervention survey scores to 
assess immediate knowledge improvement after the education. Then three months later, another 
post-intervention survey was sent out, again with the same questions and answers, again 
scrambled in their order. This survey was compared to both the pre-intervention and initial post-
intervention survey to assess knowledge retention amongst the APP’s (Appendix 2).  
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Education Intervention 	
Nurse Education.  	
Nurses that agreed to participate were then asked to attend a powerpoint education session that 
lasted about 30 minutes, including time for case studies and questions. These education sessions were 
focused on educating nursing staff on the guidelines, how/why they are utilized, and reviewing the 
important sections that can be utilized for both prevention and management of CINV. There were nine 
education sessions offered to the nursing staff over a period of four weeks to allow everyone access to the 
sessions. It was decided that it would be easier to provide education to nurses on a day they were 
scheduled to work, instead of holding education sessions at staff meetings or on additional days, as most 
people would rather call in and would not be immediately present for the education. For day shift nurses, 
the education sessions were from noon to 1pm, with lunch provided to allow people to use their lunch 
break to attend the session. On night shift, the education session were offered from 12:30 am to 1:30 am, 
again with food provided, to allow them to attend on their break. Days for the sessions were decided 
based on ensuring that every nurse, both night and day shifts, was working on a day the education 
sessions were provided. Sessions were announced to all the nurses 20 minutes prior to starting, and the 
unit was split so that half of the nurses attended the first session so that the floor and patients would still 
be covered. This allowed for most of the nurses to be able to attend the entire education session. For those 
fourteen nurses unable to attend, and those that may not have been able to stay for the entire session, and 
voice-recorded powerpoint presentation was emailed out for everyone to listen to and/or review.  
APP Education.  
All the APP’s agreed to participate, and were then asked to attend a powerpoint education session 
lasting about 30 minutes total, including time for case studies and questions. These powerpoint sessions 
were focused on; basic guideline education, discussing how to implement guidelines, antiemetics for both 
prevention and management, and the importance in utilizing them for quality patient care. The APP’s  
received additional education, specifically on the use of ASCO and NCCN clinical guidelines, and how to 
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effectively implement them into practice. There was one powerpoint education session offered to the 
APP’s during one of their weekly meetings, which captured five out of the six. For the one APP that was 
unable to attend the session in person, a voice recorded powerpoint presentation was emailed to them.  
Statistical Analysis 	
Utilizing a one-tailed homoscedastic t-test, the statistical significance was determined for each 
question in the survey for both RN’s and APP’s. A homoscedastic t-test utilizes a two-sample population 
data set that assumes both populations are equal with equal variances. This test was chosen since the 
survey was taken anonymously and not by the same people every time, therefore the two populations 
could not be paired but were determined to have equal population variances. A homoscedastic t-test was 
used for each survey question to compare pre-intervention to post-intervention, post-intervention to three 
months post-intervention, and pre-intervention to three months post-intervention for both RN’s and 
APP’s. This same test was also used to determine statistical significance of guideline adherence, CINV 
rates, and the presence of nausea/emesis between pre-education and three months post-education.  
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CHAPTER 6: RESULTS 
Primary Aim: Retrospective Chart Analysis  	
Pre-Intervention Patient Demographics. Of the 86 patients, the mean age was 55.5 years old, with the 
majority being white (61.6%) males (65.1%) (Table 1.1). The most common cancer diagnosis was 
lymphoma (64%), followed by leukemia (17.4%). Chemotherapy regimen given were classified as either 
HEC Non-AC (Anthracycline/Cyclophosphamide) regimen or HEC AC Regimen. The AC Regimen were 
more commonly given on the inpatient unit (62.8%), and R-DA-EPOCH was the most commonly given 
regimen (22.1%) (Table 1.1). Lymphoma was the most common cancer diagnosis (62.8%), followed by 
Leukemia (17.4%) (Table 1.1). 
Table 1.1: Patient Demographics Who Received HEC  
Characteristic Before Education 
Total Patients (N=86) 
3 months post ed. 
Total Patients (n=37) 
Age – years (%)   
Median 55.5 (20-88) 55 (24-76) 
Age by Decade    
20-29 12 (14%) 3 (8.1%) 
30-39 10 (11.6%) 8 (21.6%) 
40-49 11 (12.8%) 4 (10.9%) 
50-59 20 (23.2%) 8 (21.6%) 
60-69 22 (25.6%) 11 (29.7%) 
> 70 11 (12.8%) 3 (8.1%) 
Race or Ethnic Group – no. (%)   
White 53 (61.6%) 22 (59.5%) 
Black 18 (20.9%) 9 (24.3%) 
Asian 3 (3.5%)  
American Indian or Alaska Native 1 (1.2%)  
Hispanic 11 (12.8%) 6 (16.2%) 
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Sex – no. (%)   
Female 30 (34.9%) 7 (18.9%) 
Male 56  (65.1%) 30 (81.1%) 
 
Cancer Diagnosis   
Leukemia 15 (17.4%) 4 (10.8%) 
ALL 13 (15.1%) 3 (8.1%) 
Plasma Cell Leukemia  2 (2.3%) 1 (2.7%) 
Lymphoma 54 (62.8%) 25 (67.6%) 
Burkitt’s Lymphoma 10 (11.5%) 2 (5.4%) 
CNS Lymphoma  1 (1.2%) 1 (2.7%) 
Diffuse Lg B-cell Lymphoma  (DLBCL) 28 (32.5%) 19 (51.4%) 
T-cell Lymphoma 3 (3.5%) 2 (5.4%) 
Hodgkin Lymphoma  1 (1.2%) 1 (2.7%) 
Anaplastic Lg Cell Lymphoma  4 (4.6%)  
Mantle Cell Lymphoma 3 (3.5%)  
Follicular Lymphoma 1 (1.2%)  
Lymphoplasmacytic Lymphoma 1 (1.2%)  
Double Hit Lymphoma 1 (1.2%)  
EBV Associated Lymphoma 1 (1.2%)  
Testicular Cancer 3 (3.5%) 3 (8.1%) 
Sarcoma 5 (5.8%) 1 (2.7%) 
Multiple Myeloma  8 (9.3%) 2 (5.4%) 
Small Cell Lung Cancer (SCLC) 1 (1.2%)  
Ethmoid Sinus Cancer  1 (2.7%) 
Mycosis Fungoides   1 (2.7%) 
Chemotherapy Regimen Name – no. (%)   
HEC Chemotherapy (Non AC Regimen*)  (n=32) 37.2% (n=18) 48.6% 
ICE (Ifosfamide + Carboplatin + 
Etoposide) 
4 (4.6%) 5 (13.5%) 
R-ICE (Rituximab + ICE) 6 (7%) 2 (5.4%) 
MM VDT PACE (Bortezomib + Cisplatin 
+ Cyclophosphamide + Etoposide + 
9 (10.5%) 3 (8.1%) 
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Doxorubicin) 
BEP (Bleomycin + Etoposide + Cisplatin)  1 (1.2%) 1 (2.7%) 
Lung SCLC XRT Cisplatin/Etoposide  1 (1.2%) 1 (2.7%) 
ICE + Romidepsin  2  (2.3%)  
ICE + Ofatumumab  1 (1.2%)  
Doxorubicin/Ifosfamide 5 (5.8%)  
TI-CE (Paclitaxel + Ifosfamide) 1 (1.2%)  
VIP (Etoposide + Ifosfamide + Cisplatin) 1 (1.2%)  
Cyclophosphamide + Bortezomib + 
Dexamethasone 
1 (1.2%)  
R-MVP (Rituximab + Methotrexate + 
Vincristine + PO Procarbazine) 
 1 (2.7%) 
Etoposide/Cisplatin  1 (2.7%) 
Sarcoma: Ifosfamide/Mesna  1 (2.7%) 
TIP (Paclitaxel + Ifosfamide + Cisplatin)   1 (2.7%) 
R-DHAP (Rituximab + High Dose 
Cytarabine + Cisplatin) 
 2 (5.4%)  
HEC Chemotherapy (AC Regimen*)  (n=54) 62.8% (n=19) 51.4% 
*DA-EPOCH (Etoposide + Vincristine + 
Doxorubicin + Cyclophosphamide)  
2 (2.3%) 1 (2.7%) 
Hyper CVAD (Vincristine + 
Cyclophosphamide + Doxorubicin)  
8 (9.3%) 3 (8.1%) 
R-CHOP (Rituximab + Cyclophosphamide 
+ Doxorubicin + Vincristine)  
8 (9.3) 3 (8.1%) 
R-Hyper CVAD (Rituximab + Hyper 
CVAD) 
8 (9.3) 1 (2.7%) 
R-DA-EPOCH (Rituximab + DA-EPOCH) 19 (22.1%) 7 (18.9%) 
R-EPOCH (Rituximab + EPOCH) 1 (1.2%) 4 (10.8%) 
B-DA-EPOCH (Bortezomib + DA-
EPOCH) 
3 (3.5%)  
Hyper CVAD + Dasatinib 1 (1.2%)  
R-Hyper CVAD + Dasatinib  3 (3.5%)  
*(DA = Dose Adjusted); (AC = Anthracycline + Cyclophosphamide)  
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Pre-intervention Chart Analysis.  	
The UNC i2b2 data queries submitted to the CDW returned 400 patient medical record numbers 
(MRN) that met the inclusion criteria. These MRN’s were provided in two separate lists; one for all 
individual HEC agents, and one for the combination of anthracyclines and cyclophosphamide. The lists 
were combined, and all duplicates were removed, which left 294 patient MRN’s for the chart review. All 
294 charts were reviewed to make sure that each chart met the inclusion criteria in the allotted time frame 
from July 2015 to July 2016. During chart audits patient charts were excluded if (Table 1.6); patient 
didn’t receive the chemotherapy on the inpatient hematology/oncology unit (n=66), received the inclusion 
chemotherapy prior to July 2015 (n=38), chemotherapy did not match inclusion parameters because of 
dosing (n=30), or the patient did not receive HEC (n=74). This left 86 patient charts that met all inclusion 
criteria to be used in the pre-intervention retrospective chart audit.  
    The rates of CINV for patients receiving HEC was 48.8%, with 42 out of the 86 patients experiencing 
CINV (Table 1.2). Management of CINV consistent with guideline adherence should result in rates of 
CINV being around 20-30%, therefore rates of CINV with HEC on the inpatient hematology/oncology 
are high. One of the reasons for such elevated rates of CINV is that of the 86 patients only six received 
the guideline recommended prophylaxis for HEC regimen, meaning there was a 7% rate of adherence to 
the guidelines. The incidence of nausea in patients was higher than the incidence of vomiting (48% vs. 
21%), which was expected given that the literature suggests that nausea is more frequently experienced 
and less controlled (Table 1.2). All of the 42 patients experienced nausea, but only 19 (45.2%) of the 42 
patients experienced vomiting (Table 1.5). Of the 42 patients experiencing CINV, 25 of them (59.5%) 
received an AC regimen. The two most common AC regimen to cause CINV were HyperCVAD (35.7%) 
and DA-EPOCH (19%) (Table 4). The remaining 17 patients that experienced CINV received a Non-AC 
regimen (40.5%), with the most common regimen to cause CINV being VDT-PACE (19%) (Table 1.5).  
    Management of breakthrough CINV was most commonly managed with the use of IV and/or PO 
Compazine (prochlorperazine) in all 42 patients (100%) who experienced CINV (Table 1.4). Zofran 
(ondansetron) IV and/or PO was used to manage breakthrough CINV in 18 (40.5%) of patients, followed 
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by Ativan (lorazepam) IV and/or PO for 10 (23.8%) patients (Table 1.4). All 86 patients were 
premedicated with Zofran 24mg daily while receiving chemotherapy. There were six patients (7%) that 
received additional doses of Zofran, along with the 24 mg prophylactic dose, for management of 
breakthrough within a 24 hour period.   
Table 1.2: Presence of CINV 
Presence of CINV – no. (%) Before Education 
Total Patients (N=86) 
3 months post ed. 
Total Patients (n=37) 
P-Value 
Yes 42 (48.8%) 14 (37.8 %) 0.13 
No 44 (51.2%) 23 (62.2%)  0.13 
Experience of CINV by 
Gender no./total (%) 
   
# Female Exp CINV 13/30 (43.3%) 1 /7 (14.3%)  
# Male Exp CINV 29/56 (51.8%) 13/30 (43.3%)  
Experience of CINV by 
cancer diagnosis no./total 
(%) 
   
Leukemia 11/15 (73.3%) 3/4 (75%) 0.45 
Lymphoma 18/54 (33.3%) 5/25 (20%) 0.11 
Testicular Cancer 2/3 (66.7%) 3/3 (100%) 0.18 
Multiple Myeloma 8/8 (100%) 1/2 (50%) 0.02  
Sarcoma 3/5 (60%) 1/1 (100%)  
Chemotherapy Cycle # - no. (%)    
1 76 (88.4%) 25 (67.6%)  
≥ 2 10 (11.6%) 12 (32.4%)  
(From the retrospective patient chart audits)  
**(Comparing pre and post education, P <0.05) 
 
 
 
 
Table 1.3: Prevalence of CINV 
Results Chart Review 
Pre-Education 
(n=86) 
Chart Review 3 
mos. Post-
Education (n=37)  
P-Value** 
Patients Given Guideline 
Appropriate Premedications  
   
Not given 80 (93%)  29 (78.4%) 0.01 
Given 6 (7%) 8 (21.6%) 0.01 
Presence of Emesis (Vomiting) – no. 
(%) 
   
none 68 (79%) 31 (83.8%) 0.27 
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one time 18 (21%) 6 (16.2%) 0.27 
>1 time 11 (13%) 5 (13.5%) 0.45 
Presence of Nausea – no. (%)    
none 45 (52%) 23 (62.2%) 0.15 
one time 41 (48%) 14 (37.8%) 0.15 
>1 time  31 (36%) 9 (24.3%)  0.10 
(From the retrospective patient chart audits)  
**(Comparing pre and post education, P <0.05) 
 
Post-Intervention Patient Demographics 	
Of the 37 patients, the mean age was 55 years old, with the majority being white (59.5%) males 
(81.1%) (Table 1.1). Lymphoma was the most common cancer diagnosis (67.6%), followed by Leukemia 
(10.8%), similar to the first chart analysis (Table 1.1). Chemotherapy regimen were classified as either 
HEC Non-AC or HEC AC Regimen. As in the pre-intervention chart reviews, the AC regimen were more 
commonly given on the inpatient unit (51.4%), with R-DA-EPOCH being being given the most (18.9%). 
In this chart review, there were a few different Non-AC Regimen given then in pre-intervention chart 
review (Table 1.1).  
Post-intervention Chart Analysis  	
Three months after completion of the education intervention, the i2b2 data queries were 
submitted to the CDW, returning 78 patient MRN’s that met the inclusion criteria. The MRN’s this time 
were combined into one list by the CDW analyst, and all duplicates were removed prior to returning the 
patient MRN’s to the investigator. The same patient charts included in the first analysis were not targeted 
for this post-intervention retrospective chart review. Though the list may include some of the patients 
from the first retrospective chart review, depending on if they returned to the unit after July 2016 for 
further cycles of chemotherapy or began a new treatment regimen. All 78 charts were reviewed to make 
sure that each chart met the inclusion criteria in the allotted time frame from October 2016 to January 
2017. Patient charts were excluded if (Table 1.6); patient didn’t receive the chemotherapy on the inpatient 
hematology/oncology unit (n=9), received HEC chemotherapy prior to October 2016 (n=12), 
		 28		
chemotherapy did not match inclusion parameters because of dosing (n=13), the patient did not receive 
HEC (n=7). This left 37 patient charts that met all inclusion/exclusion criteria to be used in the post-
intervention retrospective chart audit.  
    The rate of CINV for patient receiving HEC was 37.8%, with 14 out of the 37 patient experiencing 
CINV (Table 1.2). This was an 11% decrease in the rate of CINV, but was not a significant decrease in 
the CINV rates (p=0.13) (Table 1.2). As previously stated, the rates of CINV when adhering to the 
guidelines should be 20-30%, meaning CINV rates signaled improved guideline adherence. Of the 37 
patients, eight received the guideline recommended prophylaxis for HEC, demonstrating a 21.6% rate of 
adherence to the guidelines (Table 1.3). This was a 14.6% increase in guideline adherence from pre-
intervention, which showed a significant increase in guideline adherence (p=0.01) (Table 1.3). As in the 
pre-intervention chart analysis results, the incidence of nausea in patients was higher than the incidence of 
vomiting (37.8% vs. 16.2%) (Table 1.3). All of the 14 patients experienced nausea, but only six 
experienced vomiting (16.2%) (Table 1.3). Of the 14 patients experiencing CINV, nine of them 
(64.3%)  eceived Non-AC regimen. The most common Non-AC regimen given, resulting in both nausea 
and vomiting, was VDT-PACE (14.3%) (Table 1.5). The remaining five patients that experienced CINV 
received AC Regimen (35.7%), with the most common regimen to cause CINV being Hyper-CVAD 
(21.4%) (Table 1.5).  
    Management of breakthrough CINV was most commonly managed with the use of PO and/or IV 
Compazine (prochlorperazine) in 13 of the 14 patients (92.3%) (Table 1.4). Zofran (ondansetron) IV 
and/or PO was used to manage breakthrough CINV in 5 (35.7%) of patients, followed by Ativan 
(lorazepman) IV and/or PO for 2 (14.3%) patients (Table 1.4). All 37 patients were premedicated with 
Zofran 24mg daily while receiving chemotherapy treatment. For both patients with a PRN order for 
Ativan, indications for administration stated “for anticipatory nausea/vomiting”. There were two patients 
(5.4%) that received additional doses of Zofran, along with the 24 mg prophylactic dose, for management 
of breakthrough within a 24 hour period.   
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*Table 1.4: Documentation of CINV and Antiemetics 
Documentation Chart Location of 
Nausea – no. (%) 
Pre-Education 
Intervention (n=42) 
3 mos. Post Education 
Intervention (n=14)  
**P-Value 
Nursing Note 40 (95.2%) 14 (100%)  
Nursing Assessment Flowsheet 28 (66.7%) 6 (42.9%)  
Documentation Chart Location of 
Vomiting – no. (%) 
   
Nursing Note 14 (33.3%) 5 (35.7%)   
Nursing Assessment Flowsheet 10 (23.8%) 4 (28.6%)  
Intake & Output 8 (19%) 2 (14.3%)  
Most Frequent Antiemetics Given 
for Breakthrough – no. times given 
(%) 
   
Prochlorperazine (IV and PO) 42 (100%)  13 (92.3%)  
Ondansetron (IV and PO) 18 (40.5%) 5 (35.7%)  
Lorazepam (IV and PO) 10 (23.8%) 2 (14.3%)  
Promethazine (IV and PO) 9 (21.4%) 1 (7.1%)  
Metoclopramide (IV and PO) 2 (4.8%)   
Dronabinal (PO) 1 (2.4%)   
Scopolamine Patch   1 (7.1%)   
Zofran given for breakthrough 
after 24mg given for prophylaxis – 
no. (%) 
   
Add. Zofran given  6/86 (7%)  2/37 (5.4%) 0.37 
*(From the retrospective patient chart audits) 
**(Comparing pre and post education, P <0.05) 
 
 
Table 1.5: Chemotherapy Resulting in CINV         
																																																																																						      Pre-Intervention               Post-Intervention 
Chemotherapy Regimen (Total) – no. (%) Nausea 
(n=42) 
Vomiting  
(n=19) 
Nausea 
(n=14) 
Vomiting  
(n=6) 
*HEC (Non AC Regiment- total # (%) 17 (40.5%) 8 (42%) 9 (64.3%) 4 (66.7%) 
BEP (Testicular) 1 (2.4%) 0 1 (7.1%)  
VIP (Testicular) 1 (2.4%) 1 (5.3%)   
Doxorubicin/Ifosfamide 3 (7.1%) 2 (10.5%)   
ICE/RICE 3 (7.1%) 1 (5.3%) 1 (7.1%)  
MM VDT PACE 8 (19%) 3 (15.8%) 2 (14.3%) 2 (33.3%) 
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Cyclphosphamie/Bortezimib/Dexamethasone 1 (2.4%) 1 (5.3%)   
R-DHAP   1 (7.1%) 1 (16.7%) 
Cisplatin/Etoposide    2 (14.3%)  
TIP (Testicular)    1 (7.1%)  
Ifosfamide/Mesna    1 (7.1%) 1 (16.7%) 
*HEC (AC Regimen) – total # (%) 25 (59.5%) 11 (58%) 5 (35.7%) 2 (33.3%) 
R-Hyper CVAD/Hyper CVAD 15 (35.7%) 10 
(52.6%) 
3 (21.4%)  1 (16.7%) 
R-DA-EPOCH/DA-EPOCH 8 (19%) 1 (5.3%) 1 (7.1%)  
R-CHOP 2 (4.8%) 0 1 (7.1%) 1 (16.7%) 
*(See Table 1 for chemotherapy regimen names and included chemotherapy agents) 
 
Table 1.6: Chart Exclusion Criteria 
Exclusion Criteria Pre-Intervention 
Chart Review 
(n= 208) 
Post-Intervention 
Chart Review 
(n= 41) 
Didn’t Receive Chemotherapy on the Inpatient 
Hematology/Oncology Unit 
 
66 (31.7%) 9 (22%) 
Received the Inclusion Chemotherapy Prior to 
July 2015 
 
38 (18.3%) 12 (29.3%) 
Chemotherapy Did Not Match Inclusion Criteria 
Due to Dosing 
 
30 (14.4%) 13 (31.7%) 
Patient Did Not Receive HEC 74 (35.6%) 7 (17%) 
 
 
Secondary Aim: RN/APP Survey Results 
Demographic Results.  
Table 2.1 and 2.2 summarizes the demographics of both the RN’s and APP’s for all three of the 
surveys. For the pre-intervention survey 60 nurses responded; the mean was 29.5, with the majority of 
respondents being white (81.7%) females (93.3%) with 1-5 years (61.7%) of experience in oncology.  Of 
the 60 nurses, 51 (85%) were ONS chemotherapy biotherapy certified, and only 14 (23.3%) were OCN 
certified. For the immediate post-intervention survey, 57 nurses responded; the mean was 30, with the 
majority of respondents being white (87%) females (96.4%) having 1-5 years (61.8%) of experience in 
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oncology. Of the 57 nurses, 47 (82.5%) are ONS chemotherapy/biotherapy certified, and only 13 (22.8%) 
are OCN certified. For the three months post-intervention survey, 41 nurses responded; the mean was 29, 
with the majority being white (90.3%) females (95.1%) having 1-5 years (70.7%) of experience in 
oncology. Of the 41 nurses, 38 (92.7%) were ONS chemotherapy/biotherapy certified, and 16 (39%) were 
OCN certified. Bachelor of Science in Nursing was the most common highest degree among all three 
surveys (68.3% - 75.6%). The APP’s had 5-6 respondents for each survey; the mean age was 31.6 with 
the majority being white (100%) female (81.5%) having 6-10 years (56.7%) of experience in oncology. 
All APP’s are Licensed Oncology Providers with a Masters degree specifically as an Adult Gerontology 
Nurse Practitioner or Physicians Assistant.  
Table 2.1: RN Demographics 
Characteristics  Nurses 
(n=60) 
Nurses 
(n=57) 
Nurses 
(n=41) 
Age – no. (%)     
Mean  29.5 30 29 
Age by Decade (n=58) (n=52) (n=32) 
20-29 30 (51.7%) 28 (53.8%) 17 (53%) 
30-39 13 (22.4%) 12 (23.1%) 8 (25%) 
40-49 8 (13.8%) 5 (9.6%) 6 (19%) 
50-59 7 (12.1%)  7 (13.5%)  1 (3%) 
Gender – no. (%)    
Male 4 (6.7%)  2 (3.6%) 2 (4.9%) 
Female 56 (93.3%)  54 (96.4%) 39 (95.1%) 
Race or Ethnicity – no. (%)    
White 49 (81.7%) 47 (87%) 37 (90.3%) 
Black/African American 5 (8.3%) 1 (1.9%)  
Hispanic 2 (3.3%) 1 (1.9%) 1 (2.4%) 
American Indian or Alaska Native    
Asian 1 (1.7%) 1 (1.9%) 2 (4.9%) 
Pacific Islander     
Other 3 (5%) 4 (7.4%) 1 (2.4%) 
Years of Experience in Oncology – no. (%)    
<1 yr 10 (16.7%) 11 (20%) 3 (7.3%) 
1-5 yrs. 37 (61.7%) 34 (61.8%) 29 (70.7%) 
6-10 yrs. 5 (8.3%) 5 (9.1%) 4 (9.8%) 
11-15 yrs. 5 (8.3%) 3 (5.5%) 2 (4.9%) 
16-20 yrs.  2 (3.3%) 2 (3.6%) 3 (7.3%) 
>20 yrs. 1 (1.7%)   
ONS Chemotherapy/Biotherapy Cert. – no. 
(%) 
   
Yes 51 (85%) 47 (82.5%) 38 (92.7%) 
No 9 (15%) 10 (17.5%) 3 (7.3%) 
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OCN Certified – no. (%)    
Yes 14 (23.3%)  13 (22.8%) 16 (39%) 
No 46 (76.7%) 44 (77.2%) 25 (61%) 
Highest Level of Education – no. (%)     
Diploma in Nursing 1 (1.7%) 0  1 (2.4%) 
Associates Degree  14 (23.3%) 14 (25.5%) 9 (22%) 
Bachelors of Science 41 (68.3%) 39 (70.9%) 31 (75.6%) 
Masters in Nursing 3 (5%) 1 (1.8%)  
Other Degree (in add. to nursing) 9 (15%)  7 (12.7%)  
 
Table 2.2: APP Demographics 
Characteristics  APP’s 
(n=5) 
APP’s 
(n=6) 
APP’s 
(n=5) 
Age – no. (%)     
Mean  33 32 30 
Age by Decade    
20-29 1 (20%) 2 (33.3%) 2 (40%) 
30-39 3 (60%) 3 (50%) 2 (40%) 
40-49 1 (20%) 1 (16.7%) 1 (20%) 
50-59    
Gender – no. (%)    
Male 1 (20%) 1 (16.7%) 1 (20%) 
Female 4 (80%) 5 (83.3%) 4 (80%) 
Race or Ethnicity – no. (%)    
White 5 (100%) 6 (100%) 5 (100%) 
Black/African American    
Hispanic    
American Indian or Alaska Native    
Asian    
Pacific Islander     
Other    
Years of Experience in Oncology – no. (%)    
<1 yr  1 (16.7%)  
1-5 yrs. 2 (40%) 1 (16.7%) 2 (40%) 
6-10 yrs. 3 (60%) 3 (50%) 3 (60%) 
11-15 yrs.  1 (16.7%)  
16-20 yrs.     
>20 yrs.     
Highest Level of Education – no. (%)     
Masters in Nursing 5 (100%)  6 (100%) 5 (100%) 
Are you a Licensed Oncology Provider 
(LOP)? 
   
Yes 5 (100%) 6 (100%) 5 (100%) 
No    
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Pre-Intervention Survey.  	
For the pre-intervention survey, 60 out of 82 nurses completed the survey, and five out of the six 
APP’s completed the survey (Table 2.3). The average overall score for the nurses was 57.3%, and the 
APP’s scored an average of 60.8%. Average scores were calculated by adding together the percentage 
correct for every question, then dividing the total score by the total number of questions. 
Table 2.3: Pre-Intervention Survey Participation 
 RN APP 
Participation Rates 60/82 (73%) 5/6 (83%)  
Total Average Score *692.4/13 = 57.7% *730/13 = 60.8% 
*total points correct divided by total number of questions  
 
Post-Intervention Survey.  	
For the post-intervention survey, 55 out of 78 nurses completed the survey, and all six of the 
APP’s completed the survey (Table 2.4). In the time frame of a few months, there were four nurses that 
left the unit, but only those consented and educated from the beginning were included. Post-education 
surveys showed improved results; nurses scored an average of 66.1%, and APP’s an average of 77%.   
Table 2.4: Post-Intervention Survey Participation  
 
RN APP 
Participation Rates 55/78 (70%) 6/6 (100%)  
Total Average Score *859/13 = 66.1% *935/13 = 71.9% 
*total points correct divided by total number of questions 
     
Three Month Post-Intervention Survey.  	
For the three month post-intervention survey, 41 out of the 74 nurses completed the survey, and 
five out of the six APP’s completed the survey (Table 2.5). In the three months since implementation, 
four more nurses left the unit, but again only those consented and educated from the beginning were 
included. Three months post education survey showed mix results; nurses scored an average of 66% 
showing retained knowledge, while APP’s scored an average of 68% showing a lack of knowledge 
retention.  
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Table 2.5: Three Months Post-Intervention Survey Participation  
 
RN APP 
Participation Rates 41/74 (55%) 5/6 (83%) 
Percent with Correct Responses 860/13 = 66.2% 920/13 = 70.8% 
*total points correct divided by total number of questions 
 
Managing CINV.  	
At the end of each survey, RN’s and APP’s were asked to rank their comfort in managing CINV. 
In the pre-intervention survey, the majority of nurses were either neutral or uncomfortable (54.4%) and 
the majority of APP’s were slightly comfortable (60%) (Table 2.6). Immediately after the education, 
provider comfort levels improved. The majority of nurses were slightly comfortable (63%) with less than 
20% feeling neutral or uncomfortable. APP’s all felt either slightly comfortable (50%) or extremely 
comfortable (50%). These improvements in comfort were also correlated with improved knowledge 
scores on the survey. Three months post-intervention, comfort levels remained about the same with the 
majority of nurses being slightly comfortable (73%) with managing CINV, and majority of APP’s being 
slightly comfortable (60%).  
Table 2.6: Managing CINV     
                                                   Pre-intervention               Post-intervention           3 mos. Post-intervention 
How comfortable are you 
managing CINV? –no. (%) 
Nurses 
(n=57) 
APP’s 
(n=5) 
Nurses  
(n= 46) 
APP’s 
(n=6) 
Nurses 
(n= 41) 
APP’s 
(n=5) 
Extremely comfortable 8 (13.3%) 1 (20%) 8 (17.4%) 3 (50%) 2 (4.9%) 1 (20%) 
Slightly comfortable 17 (28.3%) 3 (60%) 29 (63%) 3 (50%) 30 (73%) 3 (60%) 
Neutral 11 (18.3%) 1 (20%) 6 (13%)  5 (12.3%) 1 (20%) 
Slightly uncomfortable 16 (26.7%)  3 (6.6%)  2 (4.9%)  
Extremely uncomfortable 4 (6.7%)  0  2 (4.9%)  
 
Statistical Analysis.  	
Utilizing a one-tailed homoscedastic t-test, the statistical significance was determined for each 
question in the survey for both RN’s (Table 2.7) and APP’s (Table 2.8). Assessing their knowledge of 
where to locate the guidelines prior to education, only 4 (11.4%) of the 40 nurses that answered yes, and 2 
(50%) of the 4 APP’s knew where to fine the guidelines. This improved for the nurses after education, 
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with 17 (50%) of 44 nurses knowing where to locate the guidelines (p=0.0004). Knowledge levels of 
acute, delayed, and breakthrough CINV improved among the nurses from 33% pre-education to 55% 
post-education (p=0.01), with a significant change from pre-education to three months post-education 
(p=0.04). Also, nurses knowledge on the use of Ativan (lorazepam) for anticipatory CINV only 
significantly improve from pre-education to three months post education (p=0.002). The APP’s scores 
were relatively consistent from pre-intervention to post-intervention. Knowledge levels on the use of NK1 
RA’s pre-education were very low and showed significant improvement post-education (p=0.001) and 
three months post-education (p=0.03).  
The same one-tailed homoscedastic t-test was used to determine statistical significance of the 
overall total scores from each time period; baseline (pre-education) to EOE (end of education = post-
education), EOE to Final (three months post-education), and baseline to final (Table 3.1, 3.2). This was 
done for the both RN’s and the APP’s. No statistical significance was found for the overall total scores, 
however for both the p-values from baseline to EOE were lowest, trending in the right direction. 
Therefore, statistical significance for each questions in both surveys was determined to demonstrate areas 
of strengths and weaknesses in knowledge for both RN’s and APP’s (Table 2.7, 2.8).   
RN Survey Analysis: 	
For the RN survey, significant results were most frequently found when comparing pre-education 
to post-education for eight of thirteen questions; where to locate antiemesis guidelines, choice of 
antiemetics are based off which of the following, correctly pairing the definition with the type of CINV 
(acute, delayed, breakthrough), is management of PO HEC different than IV HEC, which antiemetic 
would you not give for a patient experiencing breakthrough CINV six hours post chemo administration, 
maximum daily dose of ondansetron, when should lorazepam be used for CINV, and which organizations 
provide antiemetic guidelines (Table 2.7). For those questions that did not show statistical significance, 
scores between the pre and post-education were very similar, demonstrating no improvement in 
knowledge (Table 2.7). Statistical significance when assessing knowledge between pre-education and 
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three months post-education were found for the following questions; where to locate antiemesis 
guidelines, choice of antiemetics are based off which of the following, correctly pairing the definition 
with the type of CINV (acute, delayed, breakthrough), and when should lorazepam be used for CINV 
(Table 2.7). Again, no statistical significance was found for questions where the scores were very similar 
between the pre and three month-post surveys. Lastly, statistical significance was found less frequently 
when comparing results from post-education to three months post-education because scores were similar, 
which demonstrates a retention of knowledge for most questions. The questions with statistical 
significance include; which of the following is true regarding emetogenicity of chemotherapy, is 
management of PO HEC different than IV HEC, and which organizations provide antiemetic guidelines 
(Table 2.7). For question number seven, no statistical significant could be calculated when comparing 
post-education to three months post-education as 100% of the nurses answered correctly each time (Table 
2.7). Questions with no statistical significance proven when comparing any time frame included; which of 
the following chemotherapy agents are considered HEC, when discharging a patient home do they need a 
script for antiemetics, and what is the purpose of an NK1-RA (Table 2.7). This was because the scores of 
all three time frames were very similar, for example when assessing the purpose of an NK1-RA the scores 
averaged in the 50’s for all three (Table 2.7).  
APP Survey Analysis 	
For the APP survey results, when assessing their understanding of where to locate the guidelines, 
no statistical significance was found because the percent correct was so similar between the pre-
education, post-education, and three months post-education (Table 2.8). Non-significant results were most 
frequently found when comparing pre-education to three months post-education results. However 
significant results for this time period were found for the question ‘what is the purpose of an NK1-RA’ 
(Table 2.8). For the pre-education to post-education time period, statistical significance was found for the  
question ‘is management of oral HEC and IV HEC different’ (Table 2.8). Lastly, from pre-education to 
post-education, statistical significance was found for the following questions; is management of oral HEC 
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and IV HEC different, and what is the purpose of an NK1-RA (Table 2.8). For question seven, no 
statistical significance was determined among all three time period because all APP’s got this question 
correct in every survey. From post-education to three months post-education, no statistical significance 
could be found for question one and question nine because all APP’s got this question correct in the 
survey during this time frame. Statistical significance was hard to prove for the APP survey results due to 
a small sample size and scores being very similar throughout the three surveys.  
 
Table 2.7: RN Qulatrics Survey Results 
Q# 
 
 
 
Q (Question) 
 
 
 
*Baseline 
P-Value 
Baseline 
to EOE 
 
*End of 
Education 
P-Value 
EOE to 
Final 
*3 months 
after 
Education 
P-Value 
Baseline 
to Final 
Q1 
Knows where to find 
CINV guidelines? – 
no. (%) 
40/60 
(66.7%) 0.10 
44/57 
(77%) 0.02 
38/41 
(93%) 0.001 
Q2 If yes than where? 4/40 (11.4%) 0.0004 
17/44 
(50%) 0.13 
8/38   
(21%) 0.03 
Q3 
Which of the 
following are 
considered highly 
emetogenic 
chemotherapy (HEC)? 
40/60 
(67%) 0.34 
40/57 
(71%) 0.28 
31/41 
(75%) 0.17 
Q4 
Choice of antiemetics 
are based on which of 
the following..? 
41/60 
(69%) 0.02 
49/57 
(86%) 0.47 
35/41 
(86%) 0.03 
Q5 
Which of following is 
paired with its correct 
statement? (acute, 
delayed, breakthrough 
CINV) 
20/60 
(33%) 0.01 
31/57 
(55%) 0.38 
22/41 
(53%) 0.04 
Q6 
Which of the 
following is TRUE 
regarding the 
emetogenicity of 
chemotherapy agents? 
10/60 
(17%) 0.45 
9/57  
(16%) 0.09 
11/41 
(28%) 0.11 
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Q7 
When discharging a 
patient home after 
receiving highly 
emetogenic 
chemotherapy, the 
patient should be 
given a prescription 
for an antiemetic even 
if they did not 
experience CINV 
during hospitalization? 
59/60 
(98%) 0.17 
57/57 
(100%) n/a 
41/41 
(100%) 0.21 
Q8 
The management of 
highly emetogenic oral 
chemotherapy is 
different than 
intravenous highly 
emetogenic 
chemotherapy? 
34/60 
(57%) 0.04 
23/57 
(40%) 0.09 
22/41 
(53%) 0.38 
Q9 
What is the purpose of 
adding a Neurokinin-1 
(NK1) receptor 
antagonist (aprepeitant 
or fosaprepitant) as a 
premedication for 
highly emetogenic 
chemotherapy? 
35/60 
(59%) 0.48 
33/57 
(58%) 0.34 
22/41 
(53%) 0.32 
Q10 
On day 1, a patient 
receives 24 mg of 
ondansetron and 8mg 
of dexamethasone as 
premedications for 
their chemotherapy 
treatment.  
The patient then 
experiences 
breakthrough nausea 6 
hours following their 
first administration, 
which of the following 
would you NOT give 
as a breakthrough 
antiemetic? 
38/60 
(63%) 0.05 
44/57 
(77%) 0.24 
29/41 
(71%) 0.22 
Q11 
Ondansetron has a 
maximum effective 
daily dose limit of 
24mg in 24 hours? 
53/60 
(89%) 0.05 
55/57 
(96%) 0.20 
38/41 
(92%) 0.24 
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Q12 
When should you use 
benzodiazepines 
(Lorazepam) for 
breakthrough CINV? 
27/60 
(45%) 0.04 
35/57 
(61%) 0.11 
30/41 
(74%) 0.002 
Q13 
Which of the 
following 
organizations provides 
antiemetic guidelines 
50/60 
(84%) 0.07 
41/57 
(72%) 0.10 
34/41 
(82%) 0.48 
EOE = end of education 
*Number of people who answered correctly/total number who took quiz 
**p <0.10 one-tailed homoscedastic t-test 
 
Table 2.8: APP Qualtrics Survey Results 
Q# 
 
Q (Question) 
 
 
 
*Baseline  
P-Value 
Baseline 
to EOE 
 
*End of 
Education 
P-Value 
EOE to 
Final 
*3 months 
after 
Education 
P-Value 
Baseline 
to Final 
Q1 
Knows where to find 
CINV guidelines? – 
no. (%) 
4/5   
(80%)  0.15 
6/6   
(100%) n/a 
5/5   
(100%) 0.17 
Q2 If yes than where? 2/4   (50%) 0.21 
4/6      
(67%) 0.42 
3/5    
(60%) 0.29 
Q3 
Choice of antiemetics 
are based on which of 
the following..? 
4/5   
(80%) 0.15 
6/6     
(100%) 0.15 
4/5     
(80%) 0.50 
Q4 
Which of the 
following is TRUE 
regarding the 
emetogenicity of 
chemotherapy 
agents? 
2/5    
(40%) 0.22 
1/6    
(17%) 0.22 
2/5    
(40%) 0.50 
Q5 
The management of 
highly emetogenic 
oral chemotherapy is 
different than 
intravenous highly 
emetogenic 
chemotherapy? 
4/5     
(80%) 0.02 
1/6     
(17%) 0.02 
4/5    
(80%) 0.50 
Q6 
What is the purpose 
of adding a 
Neurokinin-1 (NK1) 
receptor antagonist 
(aprepeitant or 
fosaprepitant) as a 
premedication for 
highly emetogenic 
1/5     
(20%) 0.001 
6/6      
(100%) 0.15 
4/5         
(80%) 0.03 
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chemotherapy? 
Q7 
Ondansetron has a 
maximum effective 
daily dose limit of 
24mg in 24 hours? 
5/5     
(100%) n/a 
6/6    
(100%) n/a 
5/5    
(100%) n/a 
Q8 
When should you use 
benzodiazepines 
(Lorazepam) for 
breakthrough CINV? 
4/5    
(80%) 0.15 
6/6    
(100%) 0.15 
4/5    
(80%) 0.50 
Q9 
Which of the 
following 
organizations 
provides antiemetic 
guidelines 
4/5    
(80%) 0.15 
6/6    
(100%) n/a 
5/5    
(100%) 0.17 
Q10 
Mrs. B is a 56 year 
old female receiving 
a highly emetogenic 
chemotherapy 
regimen. The nurse 
approaches you 
stating that Mrs. B is 
vomiting despite 
appropriate 
premedication, and 
needs an additional 
antiemetic ordered. 
Which of the 
following would you 
order for Mrs. B? 
4/5     
(80%) 0.33 
4/6    
(67%) 0.42 
3/5     
(60%) 0.27 
Q11 
Mrs. B’s primary 
nurse, you go in to 
the give the ordered 
medication but Mrs. 
B states that is has 
not helped her with 
nausea in the past. In 
this case, what would 
be the next antiemetic 
you would expect to 
be ordered for Mrs. 
B?  
2/5    
(40%) 0.38 
3/6     
(50%) 0.38 
2/5     
(40%) 0.50 
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Q12 
Palnosetron has been 
proven to be more 
effective that 
ondansetron (Zofran) 
in preventing 
chemotherapy 
induced nausea and 
vomiting (CINV)?  
1/5       
(20%) 0.17 
3/6     
(50%) 0.38 
3/5     
(60%) 0.12 
Q13 
In the recent ASCO 
guideline updates 
(2011-2015), which 
of the following 
changes have been 
made in regards to 
highly emetogenic 
chemotherapy? 
2/5     
(40%) 0.21 
4/6     
(67%) 0.21 
2/5     
(40%) 0.50 
EOE = end of education 
*Number of people who answered correctly/total number who took quiz 
**p <0.10 one-tailed homoscedastic t-test 
 
 
Table 3.1 RN Total Score Comparison 
 
Pre-
education 
score 
 
Post-
education 
score 
3 months 
post-
education 
score 
 
*P-value 
Pre-education to 
post-education 
*P-value 
Post-education to 
3 mos. post-
education 
*P-value 
Pre-education to 
3 mos. post-
education 
 
57.7% 66.1% 66.2% 0.13 0.18 0.17 
Baseline = pre-education; EOE = end of education (post-education); Final = three months post-education  
* P <0.10 one-tailed homoscedastic t-test  
 	
 
Table 3.2 APP Total Score Comparison 
Pre-
education 
score 
Post-
education 
score 
3 months 
post-
education 
score 
*P-value 
Pre-education to 
post-education 
*P-value 
Post-education to 
3 mos. post-
education 
*P-value 
Pre-education to 
3 mos. post-
education 
60.8% 71.9% 70.8% 0.16 0.19 0.29 
Baseline = pre-education; EOE = end of education (post-education); Final = three months post-education  
* P <0.10 one-tailed homoscedastic t-test  	
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CHAPTER 7: DISCUSSION 	
The aim of this quality improvement project was to both increase providers adherence to CINV 
guidelines and to decrease rates of CINV in patients receiving HEC. This study specifically aimed to 
determine if improving provider knowledge of the guidelines would improve adherence to the guidelines, 
and ultimately decrease rates of CINV. The correlation of guideline adherence and improved CINV rates 
has been widely demonstrated in research, however little has been done to assess ways to improve 
provider adherence to guidelines. Adherence rates to the CINV guidelines increased from 7% before the 
intervention to 23.3% three months after the intervention (Table 1.3). Survey scores for RN’s increased 
by about 10%, and APP’s increased by 11% after the education intervention, with nursing staff retaining 
their knowledge, and APP’s only dropping 1% in their three months post average score. This project 
demonstrates the continued need for reinforcement of guideline adherence, along with the importance of 
education health care providers on the guidelines annually. The CINV guidelines are developed and 
updated yearly, therefore guideline education should be part of all providers annual competencies.  
CINV Rates.  	
While not statistically significant, the rates of CINV did decrease from 48% before the education 
to 37.8% after the education over five months. The lack of statistical significance may be attributed to the 
variance in sample size; pre-education found 86 patients over a time span of one year, and post-education 
found 37 patients over a time span of three months. The rates of nausea were still substantially higher 
than rates of emesis, which is consistent with the current literature suggesting that the control of nausea 
remains most important in the management of CINV (Gilmore et al., 2014). Surprisingly, there was not a 
statistically significant decreased in rates of emesis between pre-education and post-education, but there 
was a statistically significant reduction in the presence of nausea. The reduction in rates of nausea is 
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contrary to the literature, which states that the experience of nausea occurs with greater frequency than 
emesis (Morrow, 2012). Control of chemotherapy induced vomiting as been reportedly advanced over the 
years, while control chemotherapy induced nausea has been less than apparent (Morrow, 2012).  
The clinical significance of improving provider knowledge and adherence to antiemesis 
guidelines is that adult receiving HEC are now receiving appropriate treatment for CINV. A statistically 
significant improvement in guideline adherence from 7% pre-education to 21.6% post-education was 
proven. Rates of adherence improved slowly overtime, suggesting that education to improve knowledge 
correlated with slight improvements in guideline adherence over three months.  
Another issue addressed with management of CINV was the use of antiemetics for breakthrough 
CINV. It is highly unlikely that breakthrough CINV will respond to an agent in the same drug class after 
unsuccessful prophylaxis with a drug from that same class (Navari, 2015). Ondansetron was the second 
most frequently given antiemetic for breakthrough, behind prochlorperazine that was used for every 
patient that experienced CINV. There was no significant improvement in decreasing the use of 
ondansetron for breakthrough CINV from pre-education to post-education. Breakthrough management is 
a difficult situation to manage, and therefore continues to be an important educational gap that needs to be 
addressed. In the literature, women are cited as having a slightly higher risk of developing CINV (Boccia, 
2013). In this study, women had lower rates of CINV than men, however more men were included in the 
study due to cancer diagnosis.  
Provider Knowledge.  	
As previously stated, one of the main purposes of this study was to determine if improving 
provider knowledge of guidelines would improve adherence to guidelines, and ultimately decrease rates 
of CINV. This project demonstrates the continued need for provider education and reinforcement of 
knowledge after implementation of this quality improvement study. In correlation to the improved 
knowledge scores of both RN’s and APP’s, improvement was shown with an 11% decrease in rates of 
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CINV three months post education. This demonstrates an almost statistically significant reduction in 
CINV rates, that can likely be related to improved provider knowledge of antiemesis guidelines.  
The survey provided to the RN’s and APP’s was utilized with the goal of determining knowledge 
barriers prior to education, assessing improvement in knowledge immediately post education, and then 
knowledge retention three months after education. In general, survey participants displayed a good basic 
knowledge of CINV and guideline management. However, the survey does indicate areas of concern 
where healthcare providers could potentially benefit from a more focused education session on those 
topics. The intents of the education was to be broad and generalized, focusing on weak areas in the initial 
survey, and demonstrating the appropriate prophylaxis for HEC along with appropriate antiemetics for 
breakthrough CINV.  
For RN’s, statistical significance was demonstrated in eight of the thirteen survey questions when 
comparing the pre-education survey results to post-education, demonstrating improved knowledge after 
the education sessions. When comparing pre-education to three months post-education, five of thirteen 
questions showed statistical significance, which demonstrated lower rates of knowledge improvement and 
instead showed that scores were similar to the pre-education scores. With more than half of the survey 
questions demonstrating significant improvement in knowledge immediately post education, and less than 
half three months post education, this underscores the importance in continuing to reinforce guideline 
knowledge.  For the APP’s, demonstrating statistical significance was difficult due to a small sample size. 
However, statistical significance was demonstrated in two of the thirteen survey questions when 
comparing pre-education to post-education. When comparing the pre-education to three months post-
education, there was only one statistically significant question, meaning that scores from both time frames 
were very similar. In some cases this meant that there was little improvement needed in knowledge (ex: 
question 7), or the knowledge levels remained the same despite education.  
These surveys demonstrated several areas of knowledge gaps that invite the need for development 
of annual education programs to continue to reinforce knowledge. Survey findings showed that despite 
receiving education on organizations that produce guidelines (NCCN, ASCO, MASCC) along with ways 
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in which to locate guidelines, RN’s and APP’s still significantly struggled with knowing where to locate 
antiemesis guidelines. The NCCN website is a weblink under common links in the electronic medical 
record (HER), however this requires a login/password to be set up, and requires one to search within 
NCCN for the guidelines. One suggestion was made to hyperlink the NCCN antiemesis guidelines into 
EPIC, however this would still require login information to access, but would provide direct access to the 
updated guidelines. NCCN pocket antiemesis guidelines were retrieved from NCCN and distributed to the 
APP’s and placed on the unit for RN use in an effort to make the guidelines more accessible.   
Another area of weakness for RN’s was in determining which chemotherapy agents were 
considered HEC, though this was only briefly presented in the education. There was little knowledge 
improvement for this question, probably related to the fact that some chemotherapy agents are considered 
HEC only when above a certain dose, which was most frequently the incorrect chemotherapy agent was 
selected. To address this knowledge gap, flagging the regimen that are considered HEC or containing 
HEC agents in EPIC with a banner in the order set would alert providers, and take out the need to know 
each individual agent. The last topic that was a major area of weakness for the RN’s was the purpose of 
adding an NK1-RA as a premedication. Education sessions discussed the importance of all three 
antiemetics (NK1-RA, 5HT-3 receptor antagonist, and dexamethasone), along with the importance of 
selecting the appropriate prophylactic agents. Given that there are numerous antiemetics available and 
discussed in the guidelines, emphasis needs to be placed on appropriate use of antiemetics (Boccia, 2013).  
Though there remained some knowledge gaps despite education, the survey identified some 
major improvements in knowledge. First, RN’s demonstrated a statistically significant knowledge 
improvement in understanding the definitions of acute, delayed, and breakthrough CINV. Understanding 
the different types of CINV is crucial to understanding the management of CINV, as early prevention of 
acute and delayed nausea is the best prevention for delayed vomiting (Gonella & Di Guilio, 2015). 
Second, they demonstrated a significant improvement in understanding the use of lorazepam for 
breakthrough CINV. The guidelines specifically address the use of lorazepam for anticipatory CINV, 
discussing that rates of anticipatory CINV decrease with appropriate use of effective prophylactic 
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antiemetic agents (NCCN, 2017). Lastly, there was a significant improvement between the pre and post-
education on the maximum daily dose of ondansetron being 24mg. Ondansetron has maximum daily dose 
limit of 24 mg, any additional doses are not harmful but with the maximum binding of receptors reached 
after 24mg, the additional doses will not be effective (GSK, 2016). Though not statistically significant, 
prior to education six (7%) of patients received ondansetron for breakthrough CINV in addition to the 
24mg prophylaxis dose in the same 24 hour period, while after education only 2 (5.4%) received 
additional ondansetron for breakthrough. The lack of statistical significance in this may again be 
contributed to the variance in sample size between the pre and post education. One suggestion to prevent 
additional doses of ondansetron from being given on days the patient is receiving 24mg for chemotherapy 
was to have a soft stop in the electronic MAR. This soft stop would alert the nurse when scanning in 
ondansetron that the patient already received the recommended max daily dose of 24mg, and ask if they 
would still like to proceed. For the nurse that is not administering the 24mg prophylaxis dose, this would 
signal to them a reminder to prevent additional doses from being given, as they will be ineffective in 
managing CINV.  
 The statistical results for the APP survey were less significant then the RN survey, which can 
likely be attributed to a much smaller population when comparing time frames of survey results. One 
large area of knowledge improvement for the APP’s was in regards to the addition of an NK1 RA and it 
purpose as a prophylactic antiemetic. Providers demonstrated improved knowledge in understanding that 
the addition of an NK1-RA was not only utilized to prevent just acute CINV, but to also prevent delayed 
CINV up to five days after administration, when combined with ondansetron and dexamethasone. 
Another interesting area of significance was the decline in knowledge from pre-education to post-
education on whether the management of CINV for PO and IV chemotherapy were different. This was 
also discussed in the education, making note that all PO HEC needs to be given ondansetron prior to 
administration, but management of delayed and breakthrough CINV is the same as for IV HEC (NCCN, 
2017). The wording of the question created confusion, which was addressed, and scores improved again 
three months post-education.  
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 One of the knowledge gaps for APP’s was in regards to understanding the emetogenicity of 
chemotherapy agents. This question assessed their understanding of the guidelines in regards to the 
emetogenicity of chemotherapy, and understanding the weakness noted in the guidelines. The purpose of 
this question was to make providers aware that while guidelines include many common chemotherapy 
agents, not all chemotherapy agents are classified in an emetogenic category, especially newer approved 
agents (Navari & Aapro, 2015). Most of the providers selected that chemotherapy agents were divided 
amongst three categories (high, moderate, and low), forgetting the minimal category. Another a 
knowledge gap for the APP’s was in administering antiemetic agents from different drug classes when 
one class is unsuccessful. The purpose of this question was to assess their understanding of the drug 
classes, and also to assess their understanding of avoiding drugs from similar classes if one is 
unsuccessful in preventing breakthrough CINV.  
In order to inform providers along the way, and discuss specific areas for improvement, a board 
was created and placed on the unit. This board informed providers of the CINV rates, the overall total 
scores of their surveys for RN’s and APP’s, and also pointed out areas in need of improvement such as 
avoiding additional doses of ondansetron. It also contained important slides from the education sessions 
for providers to reference if needed. In addition, the weekly emails sent out to all providers contained 
knowledge questions on CINV with the correct answer, to continue knowledge improvement/retention of 
knowledge. In general, the overall total scores for RN’s and APP’s increased by about 10% each from 
before education to after education, indicating that basic fundamental education and review of guidelines 
was of some value. One suggestion for improved knowledge is the development and implementation of a 
program, for nurses administering chemo and providers creating/signing chemotherapy orders, focused on 
best practice utilizing clinical guidelines for symptom management. This program should be a yearly 
requirement for all providers as a priority for all patients to receive quality cancer care.  
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Provider Adherence.  	
Improved adherence to the guidelines was assessed in two ways; decreased rates of CINV and 
increased use of guideline appropriate prophylactic regimen. The rates of CINV decreased from 48% to 
37.8%, and while not statistically significant the trend was moving in the right direction. Adherence to the 
guidelines increased from 7% pre-education to 21.6% after education over five months, demonstrating 
statistical significance and a small improvement in guideline adherence. One issue commonly addressed 
in the literature is the very limited number of studies examining different approaches to improve 
adherence to antiemetic guidelines, and those who have only showed minimal success (Jordan et. al., 
2014). Passive dissemination of education materials was determined ineffective (Jordan et al., 2014). 
While active involvement, specifically when providers received feedback about their patient’s actual 
experience of CINV, was notably effective (Jordan et. al., 2014). Providers were notified of the rates of 
CINV (48.8%), and informed of what suggested rates should be if guideline consistent prophylaxis and 
management are utilized. Upon hearing the rates, both APP’s and RN’s were highly motivated to 
participate in the education sessions and improve the care of their patients.  
 While provider adherence is difficult to assess, aside from decreasing rates of CINV and 
demonstrated improvement in administering the appropriate prophylaxis regimen, there were a few 
noticeable changes found during the retrospective chart audits. Providers were educated extensively about 
the importance of utilizing lorazepam and benzodiazapines for anticipatory CINV, or if there was an 
anxiety component to the nausea/emesis. Post-education, orders for lorazepam began to contain specific 
instructions to be given only for anticipatory CINV or if there was an anxiety component to the 
experience of CINV, which can be related to improved knowledge in the use of lorazepam. The education 
sessions also included a discussion on antiemetics that were available, discussing medications such as 
scopolamine patches and olanzapine, which were less frequently used than prochlorperazine and 
ondansetron. In the post-education session, one of the 14 patients experiencing CINV was started on a 
scopolamine patch, along with scheduled antiemeitcs. There also was an increase in the number of 
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patients on scheduled antiemetics who experienced CINV, another suggestion from the guidelines 
discussed in the education sessions.  
Overall, multiple strategies need to continually be used in order to continue guideline adherence 
and implementation of guidelines into practice. One additional approach for guideline adherence would 
be the use of financial incentives, with special attention to enforcing the value that adherence to 
guidelines can bring to cost reduction and quality improvement. The ability to motivate providers by 
improving measurable outcomes, such as CINV rates and cost reduction of healthcare cost, may be highly 
successful in improving overall guideline adherence in the organization. The lack of continued education 
for providers may directly contribute to low knowledge levels, but simple dissemination of the guidelines 
is not a sufficient solution (Navari & Aapro, 2016). Education of providers is essential to best practice, in 
addition computerized order sets should include guideline appropriate antiemetics for prophylaxis, and 
order sets including HEC should be flagged. The implementation of those changes may help to effectively 
improve adherence to guidelines and overall CINV rates.   
Guideline Adherence Changes 	
The clinical significance in improving adherence to the guidelines was that adult patients being 
treated with HEC were now receiving appropriate treatment and management of CINV. Numerous studies 
have proven that CINV incidence is significantly reduced in patients who receive guideline appropriate 
prophylactic regimen (Dushenkov et al., 2016). As outlined in NCCN, ASCO, and MASCC guidelines, 
fosaprepitant (intravenous form) or aprepitant (oral form) in combination with a corticosteroid and a 
5HT3 receptor antagonist is recommended for the prevention of CINV in patients receiving HEC (NCCN, 
2017; Hesketh et al., 2015; Herrstedt et al., 2016). However, aprepitant/fosaprepitant is extensively 
metabolized through the CYP450 system in the liver, resulting in possible drug interactions with 
antineoplastics and many other drugs used in supportive cancer care (Dushenkov et al., 2016). In a study 
by Dushenkov et. al., they determined that there were some potentially significant interactions resulting in 
an over or under exposure of the antineoplastic agents such as doxorubicin, etoposide, vincristine, along 
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with dexamethasone. Given that many of the HEC regimen given in this study included ifosfamide, 
etoposide, vincristine, doxorubicin, and dexamethasone it was decided to use an alternative recommended 
prophylactic regimen for CINV. This was an unanticipated finding from this project that was originally 
suggesting the use of NK1 RA’s to being given along with dexamethasone and ondansetron.  
However, recently both the NCCN and MASCC guidelines provide recommendations for the 
alternative use of olanzapine in place of an NK1 receptor antagonist for patient receiving HEC. ASCO 
guidelines, last updated in 2015, mention the emerging interest of olanzapine but did not have adequate 
evidence-based data to support its use. The use of olanzapine in the prophylactic antiemetic regimen was 
reported effective in preventing both acute and delayed CINV based on phase 2 and phase 3 trials, along 
with a meta-analysis (NCCN, 2017). In a phase 3 study by Navari et. al. in 2016 showed that olanzapine 
compared to an NK1 RA  in combination with a 5HT3 receptor antagonist and dexamethasone was more 
effective (Navari et. al., 2016). Though there have been studies on olanzapine and its effects on CINV, 
further research is still required to confirm efficacy and determine safety profile of side effects in 
oncology populations. Given the data supporting interactions with aprepitant/fosaprepitant and many of 
the antineoplastic agents commonly given, it was decided that olanzapine would be utilized instead. For 
all the HEC regimen at the time of this study that were not utilizing guideline appropriate antiemetic 
prophylaxis, olanzapine would be slowly integrated into the treatment plans. In this study the first 
retrospective chart analysis showed that 15 (35.7%) of the 42 patients that experienced nausea received 
Hyper-CVAD regimen, with 10 (52.6%) people experiencing vomiting out of 19. Given that Hyper-
CVAD had this highest rates of CINV in this study, the decision was made to trial the use of olanzapine 
with ondansetron and dexamethasone in patients receiving Hyper-CVAD odd cycles. 
Limitations.  	
One limitation of this study was that knowledge assessments and education were only performed 
with the APP’s, and did not include the oncologists, medical residents/interns, or pharmacists. Those 
three roles also play a large part in the adherence to guidelines, and contribute to improving the rates of 
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CINV among patients. In the future the oncologists, oncology fellows, and pharmacists should be 
assessed for their knowledge on the guidelines and be provided education to ensure guideline adherence. 
As stakeholders, they also play a major role in the process of approving the use of and addition of 
antiemetics to chemotherapy templates. Another limitation was the decline in survey participation from 
the nurses, which made for accurate determination of statistical significance in knowledge improvement 
difficult to prove. The short time period of three months for the post-education retrospective chart 
analysis created a small population of patients to audit, which potentially interfered with providing 
statistical significance in CINV rates. Ideally, a retrospective chart audit should be done one year after the 
education to get a more accurate assessment of the CINV rates and guideline adherence. In the short span 
of three months, the addition of olanzapine had just been in use for about 2 months, and there was 
surprisingly a decline in the number of patients admitted inpatient for Hyper-CVAD.  
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CHAPTER 8: CONCLUSION 
 
The CINV antiemetic guidelines were created using evidence based practice to guide providers in 
preventing and managing a common side effect experienced by oncology patients. When providers 
increase their awareness on the incidence of CINV and improve their knowledge on the utilization of 
guidelines, adherence levels increase. Ultimately, this improves rates of CINV and the overall experience 
that patients perceive when coming in for their chemotherapy treatment. Overall, this study demonstrated 
an approach that effectively began improvements to guideline adherence, and decreased the total rates of 
CINV experienced among patients receiving HEC. By continuing to reinforce the use of guidelines, along 
with continuing education on guideline updates for practice, adherence rates will continue to improve and 
CINV rates will continue to decrease. This allows for institutions to consistently deliver the best evidence 
based care to their patients.  
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APPENDIX A: RN QUALTRICS SURVEY 
Q1 What is your age? 
Q2 What is your gender? 
m Male 
m Female 
Q3 What is your ethnicity? 
m White 
m Black or African American 
m American Indian or Alaska Native 
m Asian 
m Native Hawaiian or Pacific Islander 
m Hispanic 
m Other 
Q4 What is the highest level of education that you have received? 
m Diploma in Nursing 
m Associates Degree in Nursing 
m Bachelors of Science in Nursing 
m Masters Degree in Nursing 
m PhD in Nursing 
m Doctorate of Nursing Practice 
m Degree in Field other than Nursing 
m Degree in Field other than Nursing: ____________________ 
Q5 Are you OCN certified? 
m Yes 
m No 
Q6 Are you Chemotherapy/Biotherapy Certified? 
m Yes 
m No 
Q7 Did you take the ONS Chemotherapy/Biotherapy certification course? (hint: if you were certified at 
UNC, the answer is yes!) 
m Yes 
m No 
Q8 How many years of experience have you had in Oncology Nursing? 
___________________________ 
Q9 If you have experience in nursing outside of oncology, how many total years and in what areas have 
you also worked? __________________ 
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Q10 Do you know where to locate antiemetic guidelines for management of chemotherapy induced 
nausea and vomiting (CINV)? 
m Yes 
m No 
Q11 If yes, where would you find them? ___________________________ 
Q12 Which of the following are considered highly emetogenic chemotherapy (HEC)? Select all the apply: 
q Ifosfamide 
q Cisplatin 
q Carboplatin 
q Cyclophosphamide > 1,500 mg/m2 
q AC Combination (anthracycline + cyclophosphamide) 
Q13 The choice of antiemetics is (are) based on which of the following: 
m Emetogenic potential of chemotherapy 
m Prior experience with antiemetics 
m Patient factors (age, gender, co-morbidities) 
m A and C 
m All of the above 
Q14 Which of the following is paired with its correct statement? 
m Breakthrough CINV has a specific sections within the guidelines for management 
m Acute CINV occurs within 12 hours after initiation of treatment 
m Delayed CINV occurs up to 3 days after completion of chemotherapy 
Q15 Which of the following is TRUE regarding the emetogenicity of chemotherapeutic agents? 
m Chemotherapy agents emetogenicity effects are not categorized based of their dose 
m Guidelines classify chemotherapy agents into only 3 risk groups: high, moderate, low 
m Anthracyclines (doxorubicin or epirubicin, for example) and cyclophosphamide given together 
are NOT considered highly emetogenic 
m Not all chemotherapy agents have been grouped into a risk category based on emetogenicity 
Q16 When discharging a patient home after receiving highly emetogenic chemotherapy, the patient 
should be given a prescription for an antiemetic even if they did not experience CINV during their 
hospitalization? 
m True 
m False 
Q17 The management of highly emetogenic ORAL chemotherapy is different than highly emetogenic IV 
chemotherapy? 
m True 
m False 
Q18 What is the purpose of adding the Neurokinin-1 (NK1) receptor antagonist (ex: aprepitant or 
fosaprepitant) as a pre-medication for highly emetogenic chemotherapy? 
m Its efficacy has not been continuously proven, therefore UNC does not typically give it 
m To prevent delayed CINV 
m To prevent acute CINV 
m To prevent both acute and delayed CINV 
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Q19 UNC follows the American Society of Clinical Oncology (ASCO) and National Comprehensive 
Cancer Center (NCCN) recommended CINV guidelines for the management of highly emetogenic 
chemotherapy? 
m True 
m False 
Q20 On day 1, a patient receives 24mg of ondansetron and 8mg of dexamethasone as pre-medications for 
their chemotherapy treatment. The patient then experiences breakthrough nausea 6 hours following that 
first chemotherapy administration. Which of the following would you NOT give as a breakthrough 
antiemetic? 
m ondansetron (Zofran) 4mg ODT 
m lorazepam (Ativan) 0.5mg IV 
m prochlorperazine (Compazine) 10mg PO 
m Scopolamine patch 
Q21 Ondansetron has a maximum daily dose limit of 24 mg in a 24 hour period? 
m True 
m False 
Q22 When should you use benzodiazepines (Lorazepam) for breakthrough CINV? 
m If in the standing order set 
m When compazine is ineffective 
m For patients with a history of anxiety 
m For anticipatory nausea 
Q23 Which of the following organizations provide antiemetic guidelines? 
m MASCC: Multinational Association of Supportive Care in Cancer 
m NCCN: National Comprehensive Cancer Center 
m ASCO: American Society of Clinical Oncology 
m All of the above 
Q24 After responding to these questions, how comfortable do you feel with managing CINV in your 
patients? 
m Extremely comfortable 
m Slightly comfortable 
m Neither comfortable nor uncomfortable 
m Slightly uncomfortable 
m Extremely uncomfortable 
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APPENDIX B: APP QUALTRICS SURVEY 
 
Q1 What is your age? 
Q2 What is your gender? 
m Male 
m Female 
Q3 What is your ethnicity? 
m White 
m Black or African American 
m American Indian or Alaska Native 
m Asian 
m Native Hawaiian or Pacific Islander 
m Hispanic 
m Other 
Q4 What is the highest level of advance practice education that you have received? ________ 
Q5 How many years of experience have you had in Oncology? ___________ 
Q6 Are you a Limited Oncology Prescribing Provider? 
m Yes 
m No 
Q7 Do you know where to locate antiemetic guidelines for management of chemotherapy induced nausea 
and vomiting (CINV)? 
m Yes 
m No 
Q8 If yes, where would you find them? _____________ 
Q9 Mrs. B is a 56 year old female receiving a highly emetogenic chemotherapy regimen. The nurse 
approaches you stating that Mrs. B is vomiting despite appropriate premedications and needs an 
additional antiemetic ordered. Which of the following would you order for Mrs. B? 
m Benzodiazapine - lorazepam (Ativan) 0.5mg IV q6h PRN 
m 5HT3 Anatagonist - ondansetron (Zofran) PO 8mg ODT q8h PRN 
m Phenothiazine - prochlorperazine (Compazine) 10mg IV q6h PRN 
m Neurokinin-1 receptor antagonist- fosaprepitant (Emend) 150mg IV once 
Q10 Mrs. B's primary nurse goes in to give the ordered medication, but Mrs B states that it has not helped 
her with nausea in the past. Her primary nurse comes to ask for another antiemetic. What would be the 
next antiemetic you would order for Mrs. B? 
m Phenothiazine - promethazine (Phenergan) 12.5mg IV q6h PRN 
m Benzodiazapine - lorazepam (Ativan) 0.5mg IV q6h PRN 
m 5HT3 antagonist - ondansetron (Zofran) PO 8mg ODT q8h PRN 
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Q11 Palonosetron has been proven to be more effective than ondansetron (Zofran) in preventing 
chemotherapy induced nausea and vomiting (CINV). 
m True 
m False 
Q12 The choice of antiemetics is (are) based on which of the following: 
m Emetogenic potential of chemotherapy 
m Prior experience with antiemetics 
m Patient factors (age, gender, co-morbidities) 
m A and C 
m All of the above 
Q13 Which of the following is TRUE regarding the emetogenicity of chemotherapeutic agents? 
m Chemotherapy agents emetogenicity effects are not categorized based of their dose 
m Guidelines classify chemotherapy agents into only 3 risk groups: high, moderate, low 
m Anthracyclines (doxorubicin or epirubicin, for example) and cyclophosphamide given together 
are NOT considered highly emetogenic 
m Not all chemotherapy agents have been grouped into a risk category based on emetogenicity 
Q14 The management of highly emetogenic ORAL chemotherapy is different than highly emetogenic IV 
chemotherapy? 
m True 
m False 
Q15 Which of the following organizations provide antiemetic guidelines? 
m MASCC: Multinational Association of Supportive Care in Cancer 
m NCCN: National Comprehensive Cancer Center 
m ASCO: American Society of Clinical Oncology 
m All of the above 
Q16 When should you use benzodiazepines (Lorazepam) for breakthrough CINV? 
m If in the standing order set 
m When compazine is ineffective 
m For patients with a history of anxiety 
m For anticipatory nausea 
Q17 Ondansetron has a maximum daily dose limit of 24 mg in a 24 hour period? 
m True 
m False 
Q18 UNC follows the American Society of Clinical Oncology (ASCO) and National Comprehensive 
Cancer Center (NCCN) recommended CINV guidelines for the management of highly emetogenic 
chemotherapy? 
m True 
m False 
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Q19 What is the purpose of adding the Neurokinin-1 (NK1) receptor antagonist (ex: aprepitant or 
fosaprepitant) as a pre-medication for highly emetogenic chemotherapy? 
m Its efficacy has not been continuously proven, therefore UNC does not typically give it 
m To prevent delayed CINV 
m To prevent acute CINV 
m To prevent both acute and delayed CINV 
Q20 In the recent ASCO guideline updates (2011-2015), which of the following changes have been made 
in regards to highly emetogenic chemotherapy? 
m Use of NK1 receptor antagonists for highly emetogenic chemotherapy 
m The recommended use of benzodiazepines for anticipatory nausea/vomiting or an anxiety 
component to CINV only 
m The combination of anthracycline plus cyclophosphamide is considered to be highly emetogenic 
regimen 
Q21 After responding to these questions, how comfortable do you feel with managing CINV in your 
patients? 
m Extremely comfortable 
m Slightly comfortable 
m Neither comfortable nor uncomfortable 
m Slightly uncomfortable 
m Extremely uncomfortable 
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APPENDIX C: RN SURVEY ANSWER KEY 
Q11. NCCN, ASCO, MASCC organization 
Q12. Cisplatin, Cyclophosphamide, AC Combination 
Q13. All of the Above 
Q14. Breakthrough CINV has a specific sections within the guidelines for management 
Q15. Not all chemotherapy agents have been grouped into a risk category based on emetogenicity 
Q16. True 
Q17. False 
Q18. To prevent both acute and delayed CINV 
Q19. Opinion question 
Q20. prochlorperazine (Compazine) 10mg PO 
Q21. True 
Q22. For patients with a history of anxiety 
Q23. All of the above 
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APPENDIX D: APP SURVEY ANSWER KEY 
 
Q8. NCCN, ASCO, MASCC organization 
Q9. Phenothiazine - prochlorperazine (Compazine) 10mg IV q6h PRN 
Q10. Benzodiazapine - lorazepam (Ativan) 0.5mg IV q6h PRN 
Q11. True 
Q12. All of the above 
Q13. Not all chemotherapy agents have been grouped into a risk category based on emetogenicity 
Q14. False 
Q15. All of the Above 
Q16. For patients with a history of anxiety 
Q17. True 
Q18. Opinion question 
Q19. To prevent both acute and delayed CINV 
Q20. The combination of anthracycline plus cyclophosphamide is considered to be highly emetogenic 
regimen 
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